# PeptideScanner evidence objects: Lanreotide

Every published version of the records placed with Lanreotide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/lanreotide.json. Selected public evidence only; not medical advice.

- Objects: 74
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00565097-lanreotide-v1"></a>

## ClinicalTrials.gov record NCT00565097

> PeptideScanner retained ClinicalTrials.gov record NCT00565097 at 2026-07-30T22:26:45.013Z. Its registry update date was 2009-02-17, and PeptideScanner's reviewed identity mapping was lanreotide.

- Evidence object: `story:clinicaltrials-gov-nct00565097-lanreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2009-02-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00565097-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct00565097-lanreotide-v1
- Content SHA-256: `6cae0731c63d1b002e905d4498761bb34dacadd4d9b3db52aa5c4a27eefb8028`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00565097 ([`ctg-observation-nct00565097-2009-02-17-7507d373d98f`](#source-ctg-observation-nct00565097-2009-02-17-7507d373d98f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00565097 at 2026-07-30T22:26:45.013Z. Its registry update date was 2009-02-17, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct00565097-2009-02-17-7507d373d98f`](#source-ctg-observation-nct00565097-2009-02-17-7507d373d98f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00565097 at 2026-07-30T22:26:45.013Z. Its registry update date was 2009-02-17, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct00565097-2009-02-17-7507d373d98f`](#source-ctg-observation-nct00565097-2009-02-17-7507d373d98f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00565097-2009-02-17-7507d373d98f`](#source-ctg-observation-nct00565097-2009-02-17-7507d373d98f))

### Sources

<a id="source-ctg-observation-nct00565097-2009-02-17-7507d373d98f"></a>
- **ClinicalTrials.gov record NCT00565097 · retained source version 2009-02-17:7507d373d98fb7650bba38798eb4db96adc34f2431778105b352cc0e291ee934** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00565097) (`ctg-observation-nct00565097-2009-02-17-7507d373d98f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00565097." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct00565097-lanreotide-v1 SHA-256: 6cae0731c63d1b002e905d4498761bb34dacadd4d9b3db52aa5c4a27eefb8028.

---

<a id="clinicaltrials-gov-nct00774930-lanreotide-v1"></a>

## ClinicalTrials.gov record NCT00774930

> PeptideScanner retained ClinicalTrials.gov record NCT00774930 at 2026-07-30T19:34:18.792Z. Its registry update date was 2022-10-14, and PeptideScanner's reviewed identity mapping was lanreotide.

- Evidence object: `story:clinicaltrials-gov-nct00774930-lanreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-10-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00774930-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct00774930-lanreotide-v1
- Content SHA-256: `f1929d5ac263f43000adb02444a2decda2f1721f04d1d09b69146cf7572153e4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00774930 ([`ctg-observation-nct00774930-2022-10-14-2552601a3948`](#source-ctg-observation-nct00774930-2022-10-14-2552601a3948))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00774930 at 2026-07-30T19:34:18.792Z. Its registry update date was 2022-10-14, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct00774930-2022-10-14-2552601a3948`](#source-ctg-observation-nct00774930-2022-10-14-2552601a3948))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00774930 at 2026-07-30T19:34:18.792Z. Its registry update date was 2022-10-14, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct00774930-2022-10-14-2552601a3948`](#source-ctg-observation-nct00774930-2022-10-14-2552601a3948))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00774930-2022-10-14-2552601a3948`](#source-ctg-observation-nct00774930-2022-10-14-2552601a3948))

### Sources

<a id="source-ctg-observation-nct00774930-2022-10-14-2552601a3948"></a>
- **ClinicalTrials.gov record NCT00774930 · retained source version 2022-10-14:2552601a394812b0cf57f21a1e1ce77b6c64078dcac3c0d1afa181d9232d57ac** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00774930) (`ctg-observation-nct00774930-2022-10-14-2552601a3948`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00774930." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct00774930-lanreotide-v1 SHA-256: f1929d5ac263f43000adb02444a2decda2f1721f04d1d09b69146cf7572153e4.

---

<a id="clinicaltrials-gov-nct01354405-lanreotide-v1"></a>

## ClinicalTrials.gov record NCT01354405

> PeptideScanner retained ClinicalTrials.gov record NCT01354405 at 2026-07-30T21:54:46.540Z. Its registry update date was 2014-07-09, and PeptideScanner's reviewed identity mapping was lanreotide.

- Evidence object: `story:clinicaltrials-gov-nct01354405-lanreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-07-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01354405-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct01354405-lanreotide-v1
- Content SHA-256: `f822f2fadc596ecff2e58b83ac10c385a758ef0b5e882ad0cc8bdfb7fd6306d0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01354405 ([`ctg-observation-nct01354405-2014-07-09-73f5a87d9ec2`](#source-ctg-observation-nct01354405-2014-07-09-73f5a87d9ec2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01354405 at 2026-07-30T21:54:46.540Z. Its registry update date was 2014-07-09, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct01354405-2014-07-09-73f5a87d9ec2`](#source-ctg-observation-nct01354405-2014-07-09-73f5a87d9ec2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01354405 at 2026-07-30T21:54:46.540Z. Its registry update date was 2014-07-09, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct01354405-2014-07-09-73f5a87d9ec2`](#source-ctg-observation-nct01354405-2014-07-09-73f5a87d9ec2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01354405-2014-07-09-73f5a87d9ec2`](#source-ctg-observation-nct01354405-2014-07-09-73f5a87d9ec2))

### Sources

<a id="source-ctg-observation-nct01354405-2014-07-09-73f5a87d9ec2"></a>
- **ClinicalTrials.gov record NCT01354405 · retained source version 2014-07-09:73f5a87d9ec20517cd117812ffdecdcabf42001280f69b3b2427f9eb064504d1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01354405) (`ctg-observation-nct01354405-2014-07-09-73f5a87d9ec2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01354405." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct01354405-lanreotide-v1 SHA-256: f822f2fadc596ecff2e58b83ac10c385a758ef0b5e882ad0cc8bdfb7fd6306d0.

---

<a id="clinicaltrials-gov-nct02075606-lanreotide-v1"></a>

## ClinicalTrials.gov record NCT02075606

> PeptideScanner retained ClinicalTrials.gov record NCT02075606 at 2026-07-30T20:50:35.870Z. Its registry update date was 2019-06-07, and PeptideScanner's reviewed identity mapping was lanreotide.

- Evidence object: `story:clinicaltrials-gov-nct02075606-lanreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-06-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02075606-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct02075606-lanreotide-v1
- Content SHA-256: `388749d9e77cf94f69a84b29cb2defa2bfaae0c61e0915b40b2082fcee866158`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02075606 ([`ctg-observation-nct02075606-2019-06-07-2b3824e73b3a`](#source-ctg-observation-nct02075606-2019-06-07-2b3824e73b3a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02075606 at 2026-07-30T20:50:35.870Z. Its registry update date was 2019-06-07, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct02075606-2019-06-07-2b3824e73b3a`](#source-ctg-observation-nct02075606-2019-06-07-2b3824e73b3a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02075606 at 2026-07-30T20:50:35.870Z. Its registry update date was 2019-06-07, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct02075606-2019-06-07-2b3824e73b3a`](#source-ctg-observation-nct02075606-2019-06-07-2b3824e73b3a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02075606-2019-06-07-2b3824e73b3a`](#source-ctg-observation-nct02075606-2019-06-07-2b3824e73b3a))

### Sources

<a id="source-ctg-observation-nct02075606-2019-06-07-2b3824e73b3a"></a>
- **ClinicalTrials.gov record NCT02075606 · retained source version 2019-06-07:2b3824e73b3a07f92b226ecc654333e9b27f5476ec79d2dbbb0b3f4070529ba1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02075606) (`ctg-observation-nct02075606-2019-06-07-2b3824e73b3a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02075606." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct02075606-lanreotide-v1 SHA-256: 388749d9e77cf94f69a84b29cb2defa2bfaae0c61e0915b40b2082fcee866158.

---

<a id="clinicaltrials-gov-nct02127437-lanreotide-v1"></a>

## ClinicalTrials.gov record NCT02127437

> PeptideScanner retained ClinicalTrials.gov record NCT02127437 at 2026-07-30T16:20:49.305Z. Its registry update date was 2026-04-08, and PeptideScanner's reviewed identity mapping was lanreotide.

- Evidence object: `story:clinicaltrials-gov-nct02127437-lanreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-08
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02127437-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct02127437-lanreotide-v1
- Content SHA-256: `6223a315c80a31c57bc03a14724cd4957df80297ad4a90c38f6e1a82dd5ffec0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02127437 ([`ctg-observation-nct02127437-2026-04-08-acbdbef18222`](#source-ctg-observation-nct02127437-2026-04-08-acbdbef18222))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02127437 at 2026-07-30T16:20:49.305Z. Its registry update date was 2026-04-08, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct02127437-2026-04-08-acbdbef18222`](#source-ctg-observation-nct02127437-2026-04-08-acbdbef18222))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02127437 at 2026-07-30T16:20:49.305Z. Its registry update date was 2026-04-08, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct02127437-2026-04-08-acbdbef18222`](#source-ctg-observation-nct02127437-2026-04-08-acbdbef18222))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02127437-2026-04-08-acbdbef18222`](#source-ctg-observation-nct02127437-2026-04-08-acbdbef18222))

### Sources

<a id="source-ctg-observation-nct02127437-2026-04-08-acbdbef18222"></a>
- **ClinicalTrials.gov record NCT02127437 · retained source version 2026-04-08:acbdbef18222cdc0e315be6f3bcad2c924cc7e847957a949ae19c0f2c838587e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02127437) (`ctg-observation-nct02127437-2026-04-08-acbdbef18222`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02127437." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct02127437-lanreotide-v1 SHA-256: 6223a315c80a31c57bc03a14724cd4957df80297ad4a90c38f6e1a82dd5ffec0.

---

<a id="clinicaltrials-gov-nct02351128-lanreotide-v1"></a>

## ClinicalTrials.gov record NCT02351128

> PeptideScanner retained ClinicalTrials.gov record NCT02351128 at 2026-07-30T21:22:00.252Z. Its registry update date was 2017-10-18, and PeptideScanner's reviewed identity mapping was lanreotide.

- Evidence object: `story:clinicaltrials-gov-nct02351128-lanreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-10-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02351128-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct02351128-lanreotide-v1
- Content SHA-256: `752612be30fb4e441d4719c4176a990d76904c35e5c3ce5073b829b649ae26cd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02351128 ([`ctg-observation-nct02351128-2017-10-18-ec87271a6bae`](#source-ctg-observation-nct02351128-2017-10-18-ec87271a6bae))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02351128 at 2026-07-30T21:22:00.252Z. Its registry update date was 2017-10-18, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct02351128-2017-10-18-ec87271a6bae`](#source-ctg-observation-nct02351128-2017-10-18-ec87271a6bae))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02351128 at 2026-07-30T21:22:00.252Z. Its registry update date was 2017-10-18, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct02351128-2017-10-18-ec87271a6bae`](#source-ctg-observation-nct02351128-2017-10-18-ec87271a6bae))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02351128-2017-10-18-ec87271a6bae`](#source-ctg-observation-nct02351128-2017-10-18-ec87271a6bae))

### Sources

<a id="source-ctg-observation-nct02351128-2017-10-18-ec87271a6bae"></a>
- **ClinicalTrials.gov record NCT02351128 · retained source version 2017-10-18:ec87271a6bae06eee170df1d4c7cabc50b79dd3eb4bfef3fda7419cb39a9bcd9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02351128) (`ctg-observation-nct02351128-2017-10-18-ec87271a6bae`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02351128." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct02351128-lanreotide-v1 SHA-256: 752612be30fb4e441d4719c4176a990d76904c35e5c3ce5073b829b649ae26cd.

---

<a id="clinicaltrials-gov-nct02493517-lanreotide-v1"></a>

## ClinicalTrials.gov record NCT02493517

> PeptideScanner retained ClinicalTrials.gov record NCT02493517 at 2026-07-30T20:57:18.712Z. Its registry update date was 2019-01-29, and PeptideScanner's reviewed identity mapping was lanreotide.

- Evidence object: `story:clinicaltrials-gov-nct02493517-lanreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-01-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02493517-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct02493517-lanreotide-v1
- Content SHA-256: `637a62086c938f31e30cfc27743820a5493af21e6e25bc7829837a646ab6c39b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02493517 ([`ctg-observation-nct02493517-2019-01-29-ab159e4189e7`](#source-ctg-observation-nct02493517-2019-01-29-ab159e4189e7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02493517 at 2026-07-30T20:57:18.712Z. Its registry update date was 2019-01-29, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct02493517-2019-01-29-ab159e4189e7`](#source-ctg-observation-nct02493517-2019-01-29-ab159e4189e7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02493517 at 2026-07-30T20:57:18.712Z. Its registry update date was 2019-01-29, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct02493517-2019-01-29-ab159e4189e7`](#source-ctg-observation-nct02493517-2019-01-29-ab159e4189e7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02493517-2019-01-29-ab159e4189e7`](#source-ctg-observation-nct02493517-2019-01-29-ab159e4189e7))

### Sources

<a id="source-ctg-observation-nct02493517-2019-01-29-ab159e4189e7"></a>
- **ClinicalTrials.gov record NCT02493517 · retained source version 2019-01-29:ab159e4189e7a6845a8b0ecd4005453044d577dd4d34085c9bb5339142732d4a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02493517) (`ctg-observation-nct02493517-2019-01-29-ab159e4189e7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02493517." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct02493517-lanreotide-v1 SHA-256: 637a62086c938f31e30cfc27743820a5493af21e6e25bc7829837a646ab6c39b.

---

<a id="clinicaltrials-gov-nct03012594-lanreotide-v1"></a>

## ClinicalTrials.gov record NCT03012594

> PeptideScanner retained ClinicalTrials.gov record NCT03012594 at 2026-07-30T20:07:13.495Z. Its registry update date was 2021-01-15, and PeptideScanner's reviewed identity mapping was lanreotide.

- Evidence object: `story:clinicaltrials-gov-nct03012594-lanreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-01-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03012594-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct03012594-lanreotide-v1
- Content SHA-256: `266366dd7a2bf398da10c80ab2a44dbfb3d423034b06aaab27011365bf27cd7f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03012594 ([`ctg-observation-nct03012594-2021-01-15-ef231d4fa94a`](#source-ctg-observation-nct03012594-2021-01-15-ef231d4fa94a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03012594 at 2026-07-30T20:07:13.495Z. Its registry update date was 2021-01-15, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct03012594-2021-01-15-ef231d4fa94a`](#source-ctg-observation-nct03012594-2021-01-15-ef231d4fa94a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03012594 at 2026-07-30T20:07:13.495Z. Its registry update date was 2021-01-15, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct03012594-2021-01-15-ef231d4fa94a`](#source-ctg-observation-nct03012594-2021-01-15-ef231d4fa94a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03012594-2021-01-15-ef231d4fa94a`](#source-ctg-observation-nct03012594-2021-01-15-ef231d4fa94a))

### Sources

<a id="source-ctg-observation-nct03012594-2021-01-15-ef231d4fa94a"></a>
- **ClinicalTrials.gov record NCT03012594 · retained source version 2021-01-15:ef231d4fa94a131d748fb2b03d110d53ede9fb393aaa0073c5e01de9fa760108** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03012594) (`ctg-observation-nct03012594-2021-01-15-ef231d4fa94a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03012594." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct03012594-lanreotide-v1 SHA-256: 266366dd7a2bf398da10c80ab2a44dbfb3d423034b06aaab27011365bf27cd7f.

---

<a id="clinicaltrials-gov-nct03043664-lanreotide-v1"></a>

## ClinicalTrials.gov record NCT03043664

> PeptideScanner retained ClinicalTrials.gov record NCT03043664 at 2026-07-30T19:11:49.726Z. Its registry update date was 2023-06-29, and PeptideScanner's reviewed identity mapping was lanreotide.

- Evidence object: `story:clinicaltrials-gov-nct03043664-lanreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-06-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03043664-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct03043664-lanreotide-v1
- Content SHA-256: `090dd316135cec53fff5d2d8700db9a6888010949b7f3df6d7f57c73c77019e0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03043664 ([`ctg-observation-nct03043664-2023-06-29-252649e95e7f`](#source-ctg-observation-nct03043664-2023-06-29-252649e95e7f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03043664 at 2026-07-30T19:11:49.726Z. Its registry update date was 2023-06-29, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct03043664-2023-06-29-252649e95e7f`](#source-ctg-observation-nct03043664-2023-06-29-252649e95e7f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03043664 at 2026-07-30T19:11:49.726Z. Its registry update date was 2023-06-29, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct03043664-2023-06-29-252649e95e7f`](#source-ctg-observation-nct03043664-2023-06-29-252649e95e7f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03043664-2023-06-29-252649e95e7f`](#source-ctg-observation-nct03043664-2023-06-29-252649e95e7f))

### Sources

<a id="source-ctg-observation-nct03043664-2023-06-29-252649e95e7f"></a>
- **ClinicalTrials.gov record NCT03043664 · retained source version 2023-06-29:252649e95e7f4fc9b21092eb9e1b3acc5c2e74375c9e0e1eb8ef358f57309dde** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03043664) (`ctg-observation-nct03043664-2023-06-29-252649e95e7f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03043664." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct03043664-lanreotide-v1 SHA-256: 090dd316135cec53fff5d2d8700db9a6888010949b7f3df6d7f57c73c77019e0.

---

<a id="clinicaltrials-gov-nct03158090-lanreotide-v1"></a>

## ClinicalTrials.gov record NCT03158090

> PeptideScanner retained ClinicalTrials.gov record NCT03158090 at 2026-07-30T19:42:14.203Z. Its registry update date was 2022-03-16, and PeptideScanner's reviewed identity mapping was lanreotide.

- Evidence object: `story:clinicaltrials-gov-nct03158090-lanreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-03-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03158090-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct03158090-lanreotide-v1
- Content SHA-256: `00076d25c407ba9ee38fae5e251eafe3936ecfac6993f5e4adf694d00475bed4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03158090 ([`ctg-observation-nct03158090-2022-03-16-8e89200a2aed`](#source-ctg-observation-nct03158090-2022-03-16-8e89200a2aed))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03158090 at 2026-07-30T19:42:14.203Z. Its registry update date was 2022-03-16, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct03158090-2022-03-16-8e89200a2aed`](#source-ctg-observation-nct03158090-2022-03-16-8e89200a2aed))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03158090 at 2026-07-30T19:42:14.203Z. Its registry update date was 2022-03-16, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct03158090-2022-03-16-8e89200a2aed`](#source-ctg-observation-nct03158090-2022-03-16-8e89200a2aed))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03158090-2022-03-16-8e89200a2aed`](#source-ctg-observation-nct03158090-2022-03-16-8e89200a2aed))

### Sources

<a id="source-ctg-observation-nct03158090-2022-03-16-8e89200a2aed"></a>
- **ClinicalTrials.gov record NCT03158090 · retained source version 2022-03-16:8e89200a2aed158687ac221171612e0f7c7ce0f117c1810dab1b85fc3cc6b6b3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03158090) (`ctg-observation-nct03158090-2022-03-16-8e89200a2aed`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03158090." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct03158090-lanreotide-v1 SHA-256: 00076d25c407ba9ee38fae5e251eafe3936ecfac6993f5e4adf694d00475bed4.

---

<a id="clinicaltrials-gov-nct03946527-lanreotide-v1"></a>

## ClinicalTrials.gov record NCT03946527

> PeptideScanner retained ClinicalTrials.gov record NCT03946527 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was lanreotide.

- Evidence object: `story:clinicaltrials-gov-nct03946527-lanreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-02
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03946527-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct03946527-lanreotide-v1
- Content SHA-256: `381ba047ad39dc70dd0e9397b7e179ed2557abc7a78ee7483b43cf945b94faec`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03946527 ([`ctg-observation-nct03946527-2026-03-02-6999199a4838`](#source-ctg-observation-nct03946527-2026-03-02-6999199a4838))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03946527 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct03946527-2026-03-02-6999199a4838`](#source-ctg-observation-nct03946527-2026-03-02-6999199a4838))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03946527 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct03946527-2026-03-02-6999199a4838`](#source-ctg-observation-nct03946527-2026-03-02-6999199a4838))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03946527-2026-03-02-6999199a4838`](#source-ctg-observation-nct03946527-2026-03-02-6999199a4838))

### Sources

<a id="source-ctg-observation-nct03946527-2026-03-02-6999199a4838"></a>
- **ClinicalTrials.gov record NCT03946527 · retained source version 2026-03-02:6999199a4838f40491adfd17965c5915b9a6461947c65106551517b76b6aba2f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03946527) (`ctg-observation-nct03946527-2026-03-02-6999199a4838`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03946527." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct03946527-lanreotide-v1 SHA-256: 381ba047ad39dc70dd0e9397b7e179ed2557abc7a78ee7483b43cf945b94faec.

---

<a id="clinicaltrials-gov-nct05048901-lanreotide-v1"></a>

## ClinicalTrials.gov record NCT05048901

> PeptideScanner retained ClinicalTrials.gov record NCT05048901 at 2026-07-30T16:20:49.324Z. Its registry update date was 2026-04-09, and PeptideScanner's reviewed identity mapping was lanreotide.

- Evidence object: `story:clinicaltrials-gov-nct05048901-lanreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05048901-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct05048901-lanreotide-v1
- Content SHA-256: `1a78fdd62bda0cb39578ef19d9a79b1f4e40636dc7c045b266136174be168da8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05048901 ([`ctg-observation-nct05048901-2026-04-09-469add9afb3b`](#source-ctg-observation-nct05048901-2026-04-09-469add9afb3b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05048901 at 2026-07-30T16:20:49.324Z. Its registry update date was 2026-04-09, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct05048901-2026-04-09-469add9afb3b`](#source-ctg-observation-nct05048901-2026-04-09-469add9afb3b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05048901 at 2026-07-30T16:20:49.324Z. Its registry update date was 2026-04-09, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct05048901-2026-04-09-469add9afb3b`](#source-ctg-observation-nct05048901-2026-04-09-469add9afb3b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05048901-2026-04-09-469add9afb3b`](#source-ctg-observation-nct05048901-2026-04-09-469add9afb3b))

### Sources

<a id="source-ctg-observation-nct05048901-2026-04-09-469add9afb3b"></a>
- **ClinicalTrials.gov record NCT05048901 · retained source version 2026-04-09:469add9afb3b7afbe257162ff7d0c7b3beea435c4a13f4e8edd86bf6b32e000e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05048901) (`ctg-observation-nct05048901-2026-04-09-469add9afb3b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05048901." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct05048901-lanreotide-v1 SHA-256: 1a78fdd62bda0cb39578ef19d9a79b1f4e40636dc7c045b266136174be168da8.

---

<a id="clinicaltrials-gov-nct06807437-lanreotide-v1"></a>

## ClinicalTrials.gov record NCT06807437

> PeptideScanner retained ClinicalTrials.gov record NCT06807437 at 2026-07-30T16:22:22.334Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was lanreotide.

- Evidence object: `story:clinicaltrials-gov-nct06807437-lanreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-31
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06807437-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct06807437-lanreotide-v1
- Content SHA-256: `7708439276513e305f3da5203e327189298271a667c1771c891bb2aa816237f6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06807437 ([`ctg-observation-nct06807437-2026-03-31-8f7bf36bed2f`](#source-ctg-observation-nct06807437-2026-03-31-8f7bf36bed2f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06807437 at 2026-07-30T16:22:22.334Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct06807437-2026-03-31-8f7bf36bed2f`](#source-ctg-observation-nct06807437-2026-03-31-8f7bf36bed2f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06807437 at 2026-07-30T16:22:22.334Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct06807437-2026-03-31-8f7bf36bed2f`](#source-ctg-observation-nct06807437-2026-03-31-8f7bf36bed2f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06807437-2026-03-31-8f7bf36bed2f`](#source-ctg-observation-nct06807437-2026-03-31-8f7bf36bed2f))

### Sources

<a id="source-ctg-observation-nct06807437-2026-03-31-8f7bf36bed2f"></a>
- **ClinicalTrials.gov record NCT06807437 · retained source version 2026-03-31:8f7bf36bed2fef244aae2511cfe1d25ca03b98df698cb69c168fef22cc868366** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06807437) (`ctg-observation-nct06807437-2026-03-31-8f7bf36bed2f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06807437." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#clinicaltrials-gov-nct06807437-lanreotide-v1 SHA-256: 7708439276513e305f3da5203e327189298271a667c1771c891bb2aa816237f6.

---

<a id="dailymed-label-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v1-v1"></a>

## Lanreotide DailyMed SPL version 1

> DailyMed lists Structured Product Labeling version 1 for the reviewed Lanreotide label family with a published date of 2024-05-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v1:v1`
- Evidence domain: Regulatory
- Date in source: 2024-05-23
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#dailymed-label-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v1-v1
- Content SHA-256: `b677b597cab2f3798a6a94719d4d0ed32a287e425d394e085a1b373f5a94fb08`

### Claims and source pins

#### Headline

Lanreotide DailyMed SPL version 1 ([`dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v1-history`](#source-dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v1-history))

#### Summary

DailyMed lists Structured Product Labeling version 1 for the reviewed Lanreotide label family with a published date of 2024-05-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v1-history`](#source-dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v1-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 1 for the reviewed Lanreotide label family with a published date of 2024-05-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v1-history`](#source-dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v1-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v1-history`](#source-dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v1-history))

### Sources

<a id="source-dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v1-history"></a>
- **DailyMed SPL SET ID 2892b4c3-0329-4d29-97ff-3b45283bbab1 · SPL version 1 · published 2024-05-23 · retained ZIP SHA-256 61b9a71fe22e8bfa99d826e900c981bd71710e9b35882f2d27565b4eda878837** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=2892b4c3-0329-4d29-97ff-3b45283bbab1&version=1) (`dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v1-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lanreotide DailyMed SPL version 1." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#dailymed-label-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v1-v1 SHA-256: b677b597cab2f3798a6a94719d4d0ed32a287e425d394e085a1b373f5a94fb08.

---

<a id="dailymed-label-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v2-v1"></a>

## Lanreotide DailyMed SPL version 2

> DailyMed lists Structured Product Labeling version 2 for the reviewed Lanreotide label family with a published date of 2024-12-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v2:v1`
- Evidence domain: Regulatory
- Date in source: 2024-12-02
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v2/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#dailymed-label-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v2-v1
- Content SHA-256: `812b0b5c18c603c6ed6e93cb293013dc71245071cc82718f2b12e06573948f6f`

### Claims and source pins

#### Headline

Lanreotide DailyMed SPL version 2 ([`dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v2-history`](#source-dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v2-history))

#### Summary

DailyMed lists Structured Product Labeling version 2 for the reviewed Lanreotide label family with a published date of 2024-12-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v2-history`](#source-dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v2-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 2 for the reviewed Lanreotide label family with a published date of 2024-12-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v2-history`](#source-dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v2-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v2-history`](#source-dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v2-history))

### Sources

<a id="source-dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v2-history"></a>
- **DailyMed SPL SET ID 2892b4c3-0329-4d29-97ff-3b45283bbab1 · SPL version 2 · published 2024-12-02 · retained ZIP SHA-256 80a2a89da89f8f25c8bd12c1437d5466f86080a346f87ea3c4d8abf9936eae49** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=2892b4c3-0329-4d29-97ff-3b45283bbab1&version=2) (`dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v2-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lanreotide DailyMed SPL version 2." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#dailymed-label-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v2-v1 SHA-256: 812b0b5c18c603c6ed6e93cb293013dc71245071cc82718f2b12e06573948f6f.

---

<a id="dailymed-label-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3-v1"></a>

## Lanreotide DailyMed SPL version 3

> DailyMed lists Structured Product Labeling version 3 for the reviewed Lanreotide label family with a published date of 2025-06-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3:v1`
- Evidence domain: Regulatory
- Date in source: 2025-06-02
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#dailymed-label-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3-v1
- Content SHA-256: `2cb0d8de18461e5d510616a8eccd8ea69fa557679ace8a50336089e4d0ec85dd`

### Claims and source pins

#### Headline

Lanreotide DailyMed SPL version 3 ([`dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3-history`](#source-dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3-history))

#### Summary

DailyMed lists Structured Product Labeling version 3 for the reviewed Lanreotide label family with a published date of 2025-06-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3-history`](#source-dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 3 for the reviewed Lanreotide label family with a published date of 2025-06-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3-history`](#source-dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3-history`](#source-dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3-history))

### Sources

<a id="source-dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3-history"></a>
- **DailyMed SPL SET ID 2892b4c3-0329-4d29-97ff-3b45283bbab1 · SPL version 3 · published 2025-06-02 · retained ZIP SHA-256 549b28079c4ff34c485706fc6353164f8e1903e90a1ec7f10f97482b441b0bfe** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=2892b4c3-0329-4d29-97ff-3b45283bbab1&version=3) (`dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lanreotide DailyMed SPL version 3." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#dailymed-label-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3-v1 SHA-256: 2cb0d8de18461e5d510616a8eccd8ea69fa557679ace8a50336089e4d0ec85dd.

---

<a id="fda-drugs-anda217193-v1"></a>

## Drugs@FDA application ANDA217193

> The official Drugs@FDA dataset lists original submission 1 for ANDA 217193 with status AP dated 2024-05-21, and names lanreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda217193:v1`
- Evidence domain: Regulatory
- Date in source: 2024-05-21
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda217193/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#fda-drugs-anda217193-v1
- Content SHA-256: `2a57a35ce319f7afa34a0b041731bfa0ff1e2885a7aa46d769a1b9c9627ac091`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA217193 ([`fda-drugs-anda217193-2024-05-21-688e02d085c4`](#source-fda-drugs-anda217193-2024-05-21-688e02d085c4))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 217193 with status AP dated 2024-05-21, and names lanreotide acetate among the application record's active ingredients. ([`fda-drugs-anda217193-2024-05-21-688e02d085c4`](#source-fda-drugs-anda217193-2024-05-21-688e02d085c4))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 217193 with status AP dated 2024-05-21, and names lanreotide acetate among the application record's active ingredients. ([`fda-drugs-anda217193-2024-05-21-688e02d085c4`](#source-fda-drugs-anda217193-2024-05-21-688e02d085c4))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda217193-2024-05-21-688e02d085c4`](#source-fda-drugs-anda217193-2024-05-21-688e02d085c4))

### Sources

<a id="source-fda-drugs-anda217193-2024-05-21-688e02d085c4"></a>
- **Drugs@FDA application ANDA217193 · original submission status AP · 2024-05-21 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA217193%22&limit=1) (`fda-drugs-anda217193-2024-05-21-688e02d085c4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA217193." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#fda-drugs-anda217193-v1 SHA-256: 2a57a35ce319f7afa34a0b041731bfa0ff1e2885a7aa46d769a1b9c9627ac091.

---

<a id="fda-drugs-anda218217-v1"></a>

## Drugs@FDA application ANDA218217

> The official Drugs@FDA dataset lists original submission 1 for ANDA 218217 with status AP dated 2026-09-18, and names lanreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda218217:v1`
- Evidence domain: Regulatory
- Date in source: 2026-09-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda218217/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#fda-drugs-anda218217-v1
- Content SHA-256: `b4df819539eb97c81b01d71b3b36705840036eb8988d8a01c58ad24b354b0227`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA218217 ([`fda-drugs-anda218217-2026-09-18-3ea852e35740`](#source-fda-drugs-anda218217-2026-09-18-3ea852e35740))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 218217 with status AP dated 2026-09-18, and names lanreotide acetate among the application record's active ingredients. ([`fda-drugs-anda218217-2026-09-18-3ea852e35740`](#source-fda-drugs-anda218217-2026-09-18-3ea852e35740))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 218217 with status AP dated 2026-09-18, and names lanreotide acetate among the application record's active ingredients. ([`fda-drugs-anda218217-2026-09-18-3ea852e35740`](#source-fda-drugs-anda218217-2026-09-18-3ea852e35740))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda218217-2026-09-18-3ea852e35740`](#source-fda-drugs-anda218217-2026-09-18-3ea852e35740))

### Sources

<a id="source-fda-drugs-anda218217-2026-09-18-3ea852e35740"></a>
- **Drugs@FDA application ANDA218217 · original submission status AP · 2026-09-18 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA218217%22&limit=1) (`fda-drugs-anda218217-2026-09-18-3ea852e35740`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA218217." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#fda-drugs-anda218217-v1 SHA-256: b4df819539eb97c81b01d71b3b36705840036eb8988d8a01c58ad24b354b0227.

---

<a id="fda-drugs-nda022074-v1"></a>

## Drugs@FDA application NDA022074

> The official Drugs@FDA dataset lists original submission 1 for NDA 022074 with status AP dated 2007-08-30, and names lanreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda022074:v1`
- Evidence domain: Regulatory
- Date in source: 2007-08-30
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda022074/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#fda-drugs-nda022074-v1
- Content SHA-256: `210d6c49cb1309e23c673529862324cdb8672f8e1572161948bb9bb1510f54d7`

### Claims and source pins

#### Headline

Drugs@FDA application NDA022074 ([`fda-drugs-nda022074-2007-08-30-439ff00e36be`](#source-fda-drugs-nda022074-2007-08-30-439ff00e36be))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 022074 with status AP dated 2007-08-30, and names lanreotide acetate among the application record's active ingredients. ([`fda-drugs-nda022074-2007-08-30-439ff00e36be`](#source-fda-drugs-nda022074-2007-08-30-439ff00e36be))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 022074 with status AP dated 2007-08-30, and names lanreotide acetate among the application record's active ingredients. ([`fda-drugs-nda022074-2007-08-30-439ff00e36be`](#source-fda-drugs-nda022074-2007-08-30-439ff00e36be))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda022074-2007-08-30-439ff00e36be`](#source-fda-drugs-nda022074-2007-08-30-439ff00e36be))

### Sources

<a id="source-fda-drugs-nda022074-2007-08-30-439ff00e36be"></a>
- **Drugs@FDA application NDA022074 · original submission status AP · 2007-08-30 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA022074%22&limit=1) (`fda-drugs-nda022074-2007-08-30-439ff00e36be`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA022074." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#fda-drugs-nda022074-v1 SHA-256: 210d6c49cb1309e23c673529862324cdb8672f8e1572161948bb9bb1510f54d7.

---

<a id="fda-drugs-nda215395-v1"></a>

## Drugs@FDA application NDA215395

> The official Drugs@FDA dataset lists original submission 1 for NDA 215395 with status AP dated 2021-12-17, and names lanreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda215395:v1`
- Evidence domain: Regulatory
- Date in source: 2021-12-17
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda215395/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#fda-drugs-nda215395-v1
- Content SHA-256: `9c033d279294971df1601bb1f7c1e1f6e736de2b82b4613e03cfeb2287aadf29`

### Claims and source pins

#### Headline

Drugs@FDA application NDA215395 ([`fda-drugs-nda215395-2021-12-17-2de401fe75fc`](#source-fda-drugs-nda215395-2021-12-17-2de401fe75fc))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 215395 with status AP dated 2021-12-17, and names lanreotide acetate among the application record's active ingredients. ([`fda-drugs-nda215395-2021-12-17-2de401fe75fc`](#source-fda-drugs-nda215395-2021-12-17-2de401fe75fc))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 215395 with status AP dated 2021-12-17, and names lanreotide acetate among the application record's active ingredients. ([`fda-drugs-nda215395-2021-12-17-2de401fe75fc`](#source-fda-drugs-nda215395-2021-12-17-2de401fe75fc))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda215395-2021-12-17-2de401fe75fc`](#source-fda-drugs-nda215395-2021-12-17-2de401fe75fc))

### Sources

<a id="source-fda-drugs-nda215395-2021-12-17-2de401fe75fc"></a>
- **Drugs@FDA application NDA215395 · original submission status AP · 2021-12-17 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA215395%22&limit=1) (`fda-drugs-nda215395-2021-12-17-2de401fe75fc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA215395." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#fda-drugs-nda215395-v1 SHA-256: 9c033d279294971df1601bb1f7c1e1f6e736de2b82b4613e03cfeb2287aadf29.

---

<a id="fda-enforcement-d-0290-2026-v1"></a>

## FDA enforcement report D-0290-2026

> FDA's dated enforcement report D-0290-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application NDA215395 through exact openFDA application-number annotations.

- Evidence object: `story:fda-enforcement-d-0290-2026:v1`
- Evidence domain: Safety
- Date in source: 2026-01-21
- Source checked: 2026-08-25
- Published by PeptideScanner: 2026-08-25
- Story landing page: https://peptidescanner.com/stories/fda-enforcement-d-0290-2026/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#fda-enforcement-d-0290-2026-v1
- Content SHA-256: `e8bef98e1214b4889f4273b8c05269acc07eec6a7a2131f840a29d9d5417256a`

### Claims and source pins

#### Headline

FDA enforcement report D-0290-2026 ([`fda-enforcement-d-0290-2026-aa4de191d243`](#source-fda-enforcement-d-0290-2026-aa4de191d243))

#### Summary

FDA's dated enforcement report D-0290-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application NDA215395 through exact openFDA application-number annotations. ([`fda-enforcement-d-0290-2026-aa4de191d243`](#source-fda-enforcement-d-0290-2026-aa4de191d243))

#### Paragraph 1

FDA's dated enforcement report D-0290-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application NDA215395 through exact openFDA application-number annotations. ([`fda-enforcement-d-0290-2026-aa4de191d243`](#source-fda-enforcement-d-0290-2026-aa4de191d243))

#### Paragraph 2

FDA's source-reported reason is: Presence of Particulate Matter. ([`fda-enforcement-d-0290-2026-aa4de191d243`](#source-fda-enforcement-d-0290-2026-aa4de191d243))

#### Paragraph 3

This PeptideScanner lane is a bounded, dated FDA enforcement-report snapshot connected through an exact openFDA application-number annotation. It is not a medical alert or complete recall-lifecycle tracker, does not establish current product or recall status, does not identify affected lots, and does not provide medical guidance. ([`fda-enforcement-d-0290-2026-aa4de191d243`](#source-fda-enforcement-d-0290-2026-aa4de191d243))

### Sources

<a id="source-fda-enforcement-d-0290-2026-aa4de191d243"></a>
- **FDA enforcement report D-0290-2026 · Class II · report date 2026-01-21 · source status Ongoing** — FDA enforcement reports via openFDA; class A. [Open source](https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0290-2026%22&limit=1) (`fda-enforcement-d-0290-2026-aa4de191d243`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA enforcement report D-0290-2026." Version 1, published 2026-08-25. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#fda-enforcement-d-0290-2026-v1 SHA-256: e8bef98e1214b4889f4273b8c05269acc07eec6a7a2131f840a29d9d5417256a.

---

<a id="fda-enforcement-d-0422-2026-v1"></a>

## FDA enforcement report D-0422-2026

> FDA's dated enforcement report D-0422-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application NDA215395 through exact openFDA application-number annotations.

- Evidence object: `story:fda-enforcement-d-0422-2026:v1`
- Evidence domain: Safety
- Date in source: 2026-04-15
- Source checked: 2026-08-25
- Published by PeptideScanner: 2026-08-25
- Story landing page: https://peptidescanner.com/stories/fda-enforcement-d-0422-2026/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#fda-enforcement-d-0422-2026-v1
- Content SHA-256: `31767245fbf6879a59e2e1e5dd90ed5e8c20b5074e2306a1cc4bd2f882178fad`

### Claims and source pins

#### Headline

FDA enforcement report D-0422-2026 ([`fda-enforcement-d-0422-2026-36fc7f6a6b04`](#source-fda-enforcement-d-0422-2026-36fc7f6a6b04))

#### Summary

FDA's dated enforcement report D-0422-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application NDA215395 through exact openFDA application-number annotations. ([`fda-enforcement-d-0422-2026-36fc7f6a6b04`](#source-fda-enforcement-d-0422-2026-36fc7f6a6b04))

#### Paragraph 1

FDA's dated enforcement report D-0422-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application NDA215395 through exact openFDA application-number annotations. ([`fda-enforcement-d-0422-2026-36fc7f6a6b04`](#source-fda-enforcement-d-0422-2026-36fc7f6a6b04))

#### Paragraph 2

FDA's source-reported reason is: Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure. ([`fda-enforcement-d-0422-2026-36fc7f6a6b04`](#source-fda-enforcement-d-0422-2026-36fc7f6a6b04))

#### Paragraph 3

This PeptideScanner lane is a bounded, dated FDA enforcement-report snapshot connected through an exact openFDA application-number annotation. It is not a medical alert or complete recall-lifecycle tracker, does not establish current product or recall status, does not identify affected lots, and does not provide medical guidance. ([`fda-enforcement-d-0422-2026-36fc7f6a6b04`](#source-fda-enforcement-d-0422-2026-36fc7f6a6b04))

### Sources

<a id="source-fda-enforcement-d-0422-2026-36fc7f6a6b04"></a>
- **FDA enforcement report D-0422-2026 · Class II · report date 2026-04-15 · source status Ongoing** — FDA enforcement reports via openFDA; class A. [Open source](https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0422-2026%22&limit=1) (`fda-enforcement-d-0422-2026-36fc7f6a6b04`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA enforcement report D-0422-2026." Version 1, published 2026-08-25. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#fda-enforcement-d-0422-2026-v1 SHA-256: 31767245fbf6879a59e2e1e5dd90ed5e8c20b5074e2306a1cc4bd2f882178fad.

---

<a id="fda-enforcement-d-0423-2026-v1"></a>

## FDA enforcement report D-0423-2026

> FDA's dated enforcement report D-0423-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application ANDA217193 through exact openFDA application-number annotations.

- Evidence object: `story:fda-enforcement-d-0423-2026:v1`
- Evidence domain: Safety
- Date in source: 2026-04-15
- Source checked: 2026-08-25
- Published by PeptideScanner: 2026-08-25
- Story landing page: https://peptidescanner.com/stories/fda-enforcement-d-0423-2026/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#fda-enforcement-d-0423-2026-v1
- Content SHA-256: `d57b3ce3826fd94f33f109d18e30ed87981339dcbc576f1afb91b352c002e820`

### Claims and source pins

#### Headline

FDA enforcement report D-0423-2026 ([`fda-enforcement-d-0423-2026-cdc37a992e40`](#source-fda-enforcement-d-0423-2026-cdc37a992e40))

#### Summary

FDA's dated enforcement report D-0423-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application ANDA217193 through exact openFDA application-number annotations. ([`fda-enforcement-d-0423-2026-cdc37a992e40`](#source-fda-enforcement-d-0423-2026-cdc37a992e40))

#### Paragraph 1

FDA's dated enforcement report D-0423-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application ANDA217193 through exact openFDA application-number annotations. ([`fda-enforcement-d-0423-2026-cdc37a992e40`](#source-fda-enforcement-d-0423-2026-cdc37a992e40))

#### Paragraph 2

FDA's source-reported reason is: Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure. ([`fda-enforcement-d-0423-2026-cdc37a992e40`](#source-fda-enforcement-d-0423-2026-cdc37a992e40))

#### Paragraph 3

This PeptideScanner lane is a bounded, dated FDA enforcement-report snapshot connected through an exact openFDA application-number annotation. It is not a medical alert or complete recall-lifecycle tracker, does not establish current product or recall status, does not identify affected lots, and does not provide medical guidance. ([`fda-enforcement-d-0423-2026-cdc37a992e40`](#source-fda-enforcement-d-0423-2026-cdc37a992e40))

### Sources

<a id="source-fda-enforcement-d-0423-2026-cdc37a992e40"></a>
- **FDA enforcement report D-0423-2026 · Class II · report date 2026-04-15 · source status Ongoing** — FDA enforcement reports via openFDA; class A. [Open source](https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0423-2026%22&limit=1) (`fda-enforcement-d-0423-2026-cdc37a992e40`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA enforcement report D-0423-2026." Version 1, published 2026-08-25. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#fda-enforcement-d-0423-2026-v1 SHA-256: d57b3ce3826fd94f33f109d18e30ed87981339dcbc576f1afb91b352c002e820.

---

<a id="federal-register-2014-17293-v1"></a>

## Federal Register notice 2014-17293

> The Federal Register published notice 2014-17293, attributed to FDA and its parent HHS department, on 2014-07-23. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Lanreotide.

- Evidence object: `story:federal-register-2014-17293:v1`
- Evidence domain: Regulatory
- Date in source: 2014-07-23
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2014-17293/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#federal-register-2014-17293-v1
- Content SHA-256: `7f055dd2cca939ab3359d5e7e556cde7cff629d32a7ecf2b2a26be222fe93252`

### Claims and source pins

#### Headline

Federal Register notice 2014-17293 ([`federal-register-2014-17293-1eaf93c9c601`](#source-federal-register-2014-17293-1eaf93c9c601))

#### Summary

The Federal Register published notice 2014-17293, attributed to FDA and its parent HHS department, on 2014-07-23. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Lanreotide. ([`federal-register-2014-17293-1eaf93c9c601`](#source-federal-register-2014-17293-1eaf93c9c601))

#### Paragraph 1

The Federal Register published notice 2014-17293, attributed to FDA and its parent HHS department, on 2014-07-23. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Lanreotide. ([`federal-register-2014-17293-1eaf93c9c601`](#source-federal-register-2014-17293-1eaf93c9c601))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2014-17293-1eaf93c9c601`](#source-federal-register-2014-17293-1eaf93c9c601))

### Sources

<a id="source-federal-register-2014-17293-1eaf93c9c601"></a>
- **Federal Register notice 2014-17293 · published 2014-07-23 · Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2014-07-23/pdf/2014-17293.pdf) (`federal-register-2014-17293-1eaf93c9c601`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2014-17293." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#federal-register-2014-17293-v1 SHA-256: 7f055dd2cca939ab3359d5e7e556cde7cff629d32a7ecf2b2a26be222fe93252.

---

<a id="federal-register-e8-27179-v1"></a>

## Federal Register notice E8-27179

> The Federal Register published notice E8-27179, attributed to FDA and its parent HHS department, on 2008-11-17. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; SOMATULINE DEPOT,” and PeptideScanner's exact reviewed identity mapping connects the document to Lanreotide.

- Evidence object: `story:federal-register-e8-27179:v1`
- Evidence domain: Regulatory
- Date in source: 2008-11-17
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-e8-27179/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#federal-register-e8-27179-v1
- Content SHA-256: `fb9095c989b6e39b95529d645da102ad4cb7a99d9040111f7ca0e790911028ca`

### Claims and source pins

#### Headline

Federal Register notice E8-27179 ([`federal-register-e8-27179-91fe25f7d5e5`](#source-federal-register-e8-27179-91fe25f7d5e5))

#### Summary

The Federal Register published notice E8-27179, attributed to FDA and its parent HHS department, on 2008-11-17. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; SOMATULINE DEPOT,” and PeptideScanner's exact reviewed identity mapping connects the document to Lanreotide. ([`federal-register-e8-27179-91fe25f7d5e5`](#source-federal-register-e8-27179-91fe25f7d5e5))

#### Paragraph 1

The Federal Register published notice E8-27179, attributed to FDA and its parent HHS department, on 2008-11-17. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; SOMATULINE DEPOT,” and PeptideScanner's exact reviewed identity mapping connects the document to Lanreotide. ([`federal-register-e8-27179-91fe25f7d5e5`](#source-federal-register-e8-27179-91fe25f7d5e5))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-e8-27179-91fe25f7d5e5`](#source-federal-register-e8-27179-91fe25f7d5e5))

### Sources

<a id="source-federal-register-e8-27179-91fe25f7d5e5"></a>
- **Federal Register notice E8-27179 · published 2008-11-17 · Determination of Regulatory Review Period for Purposes of Patent Extension; SOMATULINE DEPOT** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2008-11-17/pdf/E8-27179.pdf) (`federal-register-e8-27179-91fe25f7d5e5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice E8-27179." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#federal-register-e8-27179-v1 SHA-256: fb9095c989b6e39b95529d645da102ad4cb7a99d9040111f7ca0e790911028ca.

---

<a id="pubmed-pmid-10199803-lanreotide-v1"></a>

## PubMed record PMID 10199803

> PeptideScanner retained PubMed bibliographic metadata for PMID 10199803 at 2026-07-30T21:35:52.336Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1999-04-13. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-10199803-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-10199803-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-10199803-lanreotide-v1
- Content SHA-256: `4701c3ea679efa8a709ac8a9c118018f4c010f8f6a59dbdac6d4dc47dbca7a08`

### Claims and source pins

#### Headline

PubMed record PMID 10199803 ([`pubmed-observation-pmid-10199803-2016-11-24-76dea1f92561`](#source-pubmed-observation-pmid-10199803-2016-11-24-76dea1f92561))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 10199803 at 2026-07-30T21:35:52.336Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1999-04-13. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-10199803-2016-11-24-76dea1f92561`](#source-pubmed-observation-pmid-10199803-2016-11-24-76dea1f92561))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 10199803 at 2026-07-30T21:35:52.336Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1999-04-13. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-10199803-2016-11-24-76dea1f92561`](#source-pubmed-observation-pmid-10199803-2016-11-24-76dea1f92561))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-10199803-2016-11-24-76dea1f92561`](#source-pubmed-observation-pmid-10199803-2016-11-24-76dea1f92561))

### Sources

<a id="source-pubmed-observation-pmid-10199803-2016-11-24-76dea1f92561"></a>
- **PubMed record PMID 10199803 · retained source version 1:2016-11-24:current:76dea1f9256112b5eda8a255d04c9423185ffaed69ddb48a1990c5e8257af88b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/10199803/) (`pubmed-observation-pmid-10199803-2016-11-24-76dea1f92561`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 10199803." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-10199803-lanreotide-v1 SHA-256: 4701c3ea679efa8a709ac8a9c118018f4c010f8f6a59dbdac6d4dc47dbca7a08.

---

<a id="pubmed-pmid-10231313-lanreotide-v1"></a>

## PubMed record PMID 10231313

> PeptideScanner retained PubMed bibliographic metadata for PMID 10231313 at 2026-07-30T21:35:52.337Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1999-05-07. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-10231313-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-10231313-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-10231313-lanreotide-v1
- Content SHA-256: `c6d86efa74af0ccde15905443396f3f8ab84a7a1106fc6fad5d91d510d1695f9`

### Claims and source pins

#### Headline

PubMed record PMID 10231313 ([`pubmed-observation-pmid-10231313-2016-11-24-178cd55ce816`](#source-pubmed-observation-pmid-10231313-2016-11-24-178cd55ce816))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 10231313 at 2026-07-30T21:35:52.337Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1999-05-07. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-10231313-2016-11-24-178cd55ce816`](#source-pubmed-observation-pmid-10231313-2016-11-24-178cd55ce816))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 10231313 at 2026-07-30T21:35:52.337Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1999-05-07. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-10231313-2016-11-24-178cd55ce816`](#source-pubmed-observation-pmid-10231313-2016-11-24-178cd55ce816))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-10231313-2016-11-24-178cd55ce816`](#source-pubmed-observation-pmid-10231313-2016-11-24-178cd55ce816))

### Sources

<a id="source-pubmed-observation-pmid-10231313-2016-11-24-178cd55ce816"></a>
- **PubMed record PMID 10231313 · retained source version 1:2016-11-24:current:178cd55ce816401ca205e1489151ed72fd7a9b5989ba13d4869fc9a3e3a18639** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/10231313/) (`pubmed-observation-pmid-10231313-2016-11-24-178cd55ce816`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 10231313." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-10231313-lanreotide-v1 SHA-256: c6d86efa74af0ccde15905443396f3f8ab84a7a1106fc6fad5d91d510d1695f9.

---

<a id="pubmed-pmid-10480146-lanreotide-v1"></a>

## PubMed record PMID 10480146

> PeptideScanner retained PubMed bibliographic metadata for PMID 10480146 at 2026-07-30T21:35:52.338Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1999-09-10. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-10480146-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-10480146-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-10480146-lanreotide-v1
- Content SHA-256: `26aec1e623d04930d14930b6ef6165654bd89198f0cf11b416df35ed616eff9f`

### Claims and source pins

#### Headline

PubMed record PMID 10480146 ([`pubmed-observation-pmid-10480146-2016-11-24-a6992ef38b33`](#source-pubmed-observation-pmid-10480146-2016-11-24-a6992ef38b33))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 10480146 at 2026-07-30T21:35:52.338Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1999-09-10. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-10480146-2016-11-24-a6992ef38b33`](#source-pubmed-observation-pmid-10480146-2016-11-24-a6992ef38b33))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 10480146 at 2026-07-30T21:35:52.338Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1999-09-10. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-10480146-2016-11-24-a6992ef38b33`](#source-pubmed-observation-pmid-10480146-2016-11-24-a6992ef38b33))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-10480146-2016-11-24-a6992ef38b33`](#source-pubmed-observation-pmid-10480146-2016-11-24-a6992ef38b33))

### Sources

<a id="source-pubmed-observation-pmid-10480146-2016-11-24-a6992ef38b33"></a>
- **PubMed record PMID 10480146 · retained source version 1:2016-11-24:current:a6992ef38b334ea48031c7529594c6f1460d44f376a78659b8b6ce56f4089d3f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/10480146/) (`pubmed-observation-pmid-10480146-2016-11-24-a6992ef38b33`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 10480146." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-10480146-lanreotide-v1 SHA-256: 26aec1e623d04930d14930b6ef6165654bd89198f0cf11b416df35ed616eff9f.

---

<a id="pubmed-pmid-10579475-lanreotide-v1"></a>

## PubMed record PMID 10579475

> PeptideScanner retained PubMed bibliographic metadata for PMID 10579475 at 2026-07-30T21:35:52.340Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1999-12-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-10579475-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-10579475-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-10579475-lanreotide-v1
- Content SHA-256: `f270ba261fb897d8cf9934510ed7aef53285cc6a921b98d9ec4703807d7551b0`

### Claims and source pins

#### Headline

PubMed record PMID 10579475 ([`pubmed-observation-pmid-10579475-2016-11-24-df147568030c`](#source-pubmed-observation-pmid-10579475-2016-11-24-df147568030c))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 10579475 at 2026-07-30T21:35:52.340Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1999-12-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-10579475-2016-11-24-df147568030c`](#source-pubmed-observation-pmid-10579475-2016-11-24-df147568030c))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 10579475 at 2026-07-30T21:35:52.340Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1999-12-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-10579475-2016-11-24-df147568030c`](#source-pubmed-observation-pmid-10579475-2016-11-24-df147568030c))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-10579475-2016-11-24-df147568030c`](#source-pubmed-observation-pmid-10579475-2016-11-24-df147568030c))

### Sources

<a id="source-pubmed-observation-pmid-10579475-2016-11-24-df147568030c"></a>
- **PubMed record PMID 10579475 · retained source version 1:2016-11-24:current:df147568030cab6debe59bddb1c407a0237df703ef60b49b71908ad6f9eddb5e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/10579475/) (`pubmed-observation-pmid-10579475-2016-11-24-df147568030c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 10579475." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-10579475-lanreotide-v1 SHA-256: f270ba261fb897d8cf9934510ed7aef53285cc6a921b98d9ec4703807d7551b0.

---

<a id="pubmed-pmid-10748802-lanreotide-v1"></a>

## PubMed record PMID 10748802

> PeptideScanner retained PubMed bibliographic metadata for PMID 10748802 at 2026-07-30T21:35:52.342Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 2000-04-05. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-10748802-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-10748802-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-10748802-lanreotide-v1
- Content SHA-256: `d942bf4256313de3c390be3224a8352581a15f54c114d07bee84cc3c98f78943`

### Claims and source pins

#### Headline

PubMed record PMID 10748802 ([`pubmed-observation-pmid-10748802-2016-11-24-b9eb4c4764bf`](#source-pubmed-observation-pmid-10748802-2016-11-24-b9eb4c4764bf))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 10748802 at 2026-07-30T21:35:52.342Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 2000-04-05. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-10748802-2016-11-24-b9eb4c4764bf`](#source-pubmed-observation-pmid-10748802-2016-11-24-b9eb4c4764bf))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 10748802 at 2026-07-30T21:35:52.342Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 2000-04-05. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-10748802-2016-11-24-b9eb4c4764bf`](#source-pubmed-observation-pmid-10748802-2016-11-24-b9eb4c4764bf))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-10748802-2016-11-24-b9eb4c4764bf`](#source-pubmed-observation-pmid-10748802-2016-11-24-b9eb4c4764bf))

### Sources

<a id="source-pubmed-observation-pmid-10748802-2016-11-24-b9eb4c4764bf"></a>
- **PubMed record PMID 10748802 · retained source version 1:2016-11-24:current:b9eb4c4764bf8767e9032aebf1a3a2d299f9ce1c52145f2108953a1b27b5c549** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/10748802/) (`pubmed-observation-pmid-10748802-2016-11-24-b9eb4c4764bf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 10748802." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-10748802-lanreotide-v1 SHA-256: d942bf4256313de3c390be3224a8352581a15f54c114d07bee84cc3c98f78943.

---

<a id="pubmed-pmid-11095353-lanreotide-v1"></a>

## PubMed record PMID 11095353

> PeptideScanner retained PubMed bibliographic metadata for PMID 11095353 at 2026-07-30T21:35:52.345Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 2000-11-30. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-11095353-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-11095353-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-11095353-lanreotide-v1
- Content SHA-256: `70f2482c0dbce03b9848a4989b2effc3ae48329d28c3a2c05f81c869eee39b3c`

### Claims and source pins

#### Headline

PubMed record PMID 11095353 ([`pubmed-observation-pmid-11095353-2016-11-24-335788b8d858`](#source-pubmed-observation-pmid-11095353-2016-11-24-335788b8d858))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 11095353 at 2026-07-30T21:35:52.345Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 2000-11-30. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-11095353-2016-11-24-335788b8d858`](#source-pubmed-observation-pmid-11095353-2016-11-24-335788b8d858))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 11095353 at 2026-07-30T21:35:52.345Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 2000-11-30. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-11095353-2016-11-24-335788b8d858`](#source-pubmed-observation-pmid-11095353-2016-11-24-335788b8d858))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-11095353-2016-11-24-335788b8d858`](#source-pubmed-observation-pmid-11095353-2016-11-24-335788b8d858))

### Sources

<a id="source-pubmed-observation-pmid-11095353-2016-11-24-335788b8d858"></a>
- **PubMed record PMID 11095353 · retained source version 1:2016-11-24:current:335788b8d858df99a7bbfcfcd803f0ab5c9f267069b529f99cca7ac417d81819** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/11095353/) (`pubmed-observation-pmid-11095353-2016-11-24-335788b8d858`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 11095353." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-11095353-lanreotide-v1 SHA-256: 70f2482c0dbce03b9848a4989b2effc3ae48329d28c3a2c05f81c869eee39b3c.

---

<a id="pubmed-pmid-11128563-lanreotide-v1"></a>

## PubMed record PMID 11128563

> PeptideScanner retained PubMed bibliographic metadata for PMID 11128563 at 2026-07-30T21:35:52.346Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 2000-12-29. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-11128563-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-11128563-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-11128563-lanreotide-v1
- Content SHA-256: `a6400eb71ada062c5a4c89851aa9cd660d459f568fe82147e8295193aec526fc`

### Claims and source pins

#### Headline

PubMed record PMID 11128563 ([`pubmed-observation-pmid-11128563-2016-11-24-fd723ce8d43a`](#source-pubmed-observation-pmid-11128563-2016-11-24-fd723ce8d43a))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 11128563 at 2026-07-30T21:35:52.346Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 2000-12-29. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-11128563-2016-11-24-fd723ce8d43a`](#source-pubmed-observation-pmid-11128563-2016-11-24-fd723ce8d43a))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 11128563 at 2026-07-30T21:35:52.346Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 2000-12-29. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-11128563-2016-11-24-fd723ce8d43a`](#source-pubmed-observation-pmid-11128563-2016-11-24-fd723ce8d43a))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-11128563-2016-11-24-fd723ce8d43a`](#source-pubmed-observation-pmid-11128563-2016-11-24-fd723ce8d43a))

### Sources

<a id="source-pubmed-observation-pmid-11128563-2016-11-24-fd723ce8d43a"></a>
- **PubMed record PMID 11128563 · retained source version 1:2016-11-24:current:fd723ce8d43acff90a3d9d66dda6f4b6eba7e0a56024515e5b4a750cf3fccfaf** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/11128563/) (`pubmed-observation-pmid-11128563-2016-11-24-fd723ce8d43a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 11128563." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-11128563-lanreotide-v1 SHA-256: a6400eb71ada062c5a4c89851aa9cd660d459f568fe82147e8295193aec526fc.

---

<a id="pubmed-pmid-12037499-lanreotide-v1"></a>

## \[Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients\].

> PubMed lists PMID 12037499 in Annales d'endocrinologie as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2002-04 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-12037499-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-12037499-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-12037499-lanreotide-v1
- Content SHA-256: `b562c337fa0bddc1e1e09401ce5cc3e3347de72ab99f12e35b8160035c66f505`

### Claims and source pins

#### Headline

\[Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients\]. ([`pubmed-observation-pmid-12037499-2016-11-24-270de4f82007`](#source-pubmed-observation-pmid-12037499-2016-11-24-270de4f82007))

#### Summary

PubMed lists PMID 12037499 in Annales d'endocrinologie as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2002-04 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12037499-2016-11-24-270de4f82007`](#source-pubmed-observation-pmid-12037499-2016-11-24-270de4f82007))

#### Paragraph 1

PubMed lists PMID 12037499 in Annales d'endocrinologie as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2002-04 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12037499-2016-11-24-270de4f82007`](#source-pubmed-observation-pmid-12037499-2016-11-24-270de4f82007))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-12037499-2016-11-24-270de4f82007`](#source-pubmed-observation-pmid-12037499-2016-11-24-270de4f82007))

### Sources

<a id="source-pubmed-observation-pmid-12037499-2016-11-24-270de4f82007"></a>
- **\[Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients\]. · retained source version 1:2016-11-24:current:270de4f82007e9e9aa2a6bfbc26aae2ad1b2b3cfef7893bb3030174c3c8232a0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/12037499/) (`pubmed-observation-pmid-12037499-2016-11-24-270de4f82007`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-12037499-lanreotide-v1 SHA-256: b562c337fa0bddc1e1e09401ce5cc3e3347de72ab99f12e35b8160035c66f505.

---

<a id="pubmed-pmid-15003204-lanreotide-v1"></a>

## PubMed record PMID 15003204

> PeptideScanner retained PubMed bibliographic metadata for PMID 15003204 at 2026-07-30T21:55:37.950Z. PubMed recorded a metadata revision date of 2014-08-18 and an Entrez history date of 2004-03-09. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-15003204-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2014-08-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15003204-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-15003204-lanreotide-v1
- Content SHA-256: `8ce7e339bc3b2e9d6afc0e08ae495e97fc5bad46e08aa8339add5cf22729bb40`

### Claims and source pins

#### Headline

PubMed record PMID 15003204 ([`pubmed-observation-pmid-15003204-2014-08-18-c1124084b671`](#source-pubmed-observation-pmid-15003204-2014-08-18-c1124084b671))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 15003204 at 2026-07-30T21:55:37.950Z. PubMed recorded a metadata revision date of 2014-08-18 and an Entrez history date of 2004-03-09. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-15003204-2014-08-18-c1124084b671`](#source-pubmed-observation-pmid-15003204-2014-08-18-c1124084b671))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 15003204 at 2026-07-30T21:55:37.950Z. PubMed recorded a metadata revision date of 2014-08-18 and an Entrez history date of 2004-03-09. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-15003204-2014-08-18-c1124084b671`](#source-pubmed-observation-pmid-15003204-2014-08-18-c1124084b671))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15003204-2014-08-18-c1124084b671`](#source-pubmed-observation-pmid-15003204-2014-08-18-c1124084b671))

### Sources

<a id="source-pubmed-observation-pmid-15003204-2014-08-18-c1124084b671"></a>
- **PubMed record PMID 15003204 · retained source version 1:2014-08-18:current:c1124084b6718c6e8c4e4c47d5c3d2141c219b4eb4d3736c70184334f9ceb46c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15003204/) (`pubmed-observation-pmid-15003204-2014-08-18-c1124084b671`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 15003204." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-15003204-lanreotide-v1 SHA-256: 8ce7e339bc3b2e9d6afc0e08ae495e97fc5bad46e08aa8339add5cf22729bb40.

---

<a id="pubmed-pmid-15789272-lanreotide-v1"></a>

## Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel).

> PubMed lists PMID 15789272 in Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology \[and\] German Diabetes Association as Journal Article, with publication-date metadata of 2005-03 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15789272-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15789272-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-15789272-lanreotide-v1
- Content SHA-256: `90b96a4347d8a8bcab99dd1fd2b7860758db08a9db60c614ceab506b54c82de7`

### Claims and source pins

#### Headline

Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). ([`pubmed-observation-pmid-15789272-2026-01-28-d803d8ef110c`](#source-pubmed-observation-pmid-15789272-2026-01-28-d803d8ef110c))

#### Summary

PubMed lists PMID 15789272 in Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology \[and\] German Diabetes Association as Journal Article, with publication-date metadata of 2005-03 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15789272-2026-01-28-d803d8ef110c`](#source-pubmed-observation-pmid-15789272-2026-01-28-d803d8ef110c))

#### Paragraph 1

PubMed lists PMID 15789272 in Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology \[and\] German Diabetes Association as Journal Article, with publication-date metadata of 2005-03 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15789272-2026-01-28-d803d8ef110c`](#source-pubmed-observation-pmid-15789272-2026-01-28-d803d8ef110c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15789272-2026-01-28-d803d8ef110c`](#source-pubmed-observation-pmid-15789272-2026-01-28-d803d8ef110c))

### Sources

<a id="source-pubmed-observation-pmid-15789272-2026-01-28-d803d8ef110c"></a>
- **Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). · retained source version 1:2026-01-28:current:d803d8ef110c4653974c3a80952a3dd6ed0c8cc7285052ddf28a26605502340c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15789272/) (`pubmed-observation-pmid-15789272-2026-01-28-d803d8ef110c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel)." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-15789272-lanreotide-v1 SHA-256: 90b96a4347d8a8bcab99dd1fd2b7860758db08a9db60c614ceab506b54c82de7.

---

<a id="pubmed-pmid-15789913-lanreotide-v1"></a>

## \[Lanreotide in the treatment of thyroid orbitopathy\].

> PubMed lists PMID 15789913 in Przeglad lekarski as Journal Article, with publication-date metadata of 2004 (year precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15789913-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15789913-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-15789913-lanreotide-v1
- Content SHA-256: `937aac4405a09b46e84a69df7b1e4c65dffda6d6d89eba826df1bf8952c3c023`

### Claims and source pins

#### Headline

\[Lanreotide in the treatment of thyroid orbitopathy\]. ([`pubmed-observation-pmid-15789913-2016-11-24-5aa6edd1b8ce`](#source-pubmed-observation-pmid-15789913-2016-11-24-5aa6edd1b8ce))

#### Summary

PubMed lists PMID 15789913 in Przeglad lekarski as Journal Article, with publication-date metadata of 2004 (year precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15789913-2016-11-24-5aa6edd1b8ce`](#source-pubmed-observation-pmid-15789913-2016-11-24-5aa6edd1b8ce))

#### Paragraph 1

PubMed lists PMID 15789913 in Przeglad lekarski as Journal Article, with publication-date metadata of 2004 (year precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15789913-2016-11-24-5aa6edd1b8ce`](#source-pubmed-observation-pmid-15789913-2016-11-24-5aa6edd1b8ce))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15789913-2016-11-24-5aa6edd1b8ce`](#source-pubmed-observation-pmid-15789913-2016-11-24-5aa6edd1b8ce))

### Sources

<a id="source-pubmed-observation-pmid-15789913-2016-11-24-5aa6edd1b8ce"></a>
- **\[Lanreotide in the treatment of thyroid orbitopathy\]. · retained source version 1:2016-11-24:current:5aa6edd1b8ced1b7081a988ecceac30ae1db1656dd7a9d1bc88c71acaa6434ac** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15789913/) (`pubmed-observation-pmid-15789913-2016-11-24-5aa6edd1b8ce`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Lanreotide in the treatment of thyroid orbitopathy\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-15789913-lanreotide-v1 SHA-256: 937aac4405a09b46e84a69df7b1e4c65dffda6d6d89eba826df1bf8952c3c023.

---

<a id="pubmed-pmid-16154424-lanreotide-v1"></a>

## Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel.

> PubMed lists PMID 16154424 in Metabolism: clinical and experimental as Clinical Trial, Clinical Trial, Phase III, Journal Article, Multicenter Study, with publication-date metadata of 2005-10 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16154424-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16154424-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-16154424-lanreotide-v1
- Content SHA-256: `3a9c543d560d1de0d60038497a41ef01f2c981fa25bd809b5020697a76755b2d`

### Claims and source pins

#### Headline

Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. ([`pubmed-observation-pmid-16154424-2016-11-24-de7345724055`](#source-pubmed-observation-pmid-16154424-2016-11-24-de7345724055))

#### Summary

PubMed lists PMID 16154424 in Metabolism: clinical and experimental as Clinical Trial, Clinical Trial, Phase III, Journal Article, Multicenter Study, with publication-date metadata of 2005-10 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16154424-2016-11-24-de7345724055`](#source-pubmed-observation-pmid-16154424-2016-11-24-de7345724055))

#### Paragraph 1

PubMed lists PMID 16154424 in Metabolism: clinical and experimental as Clinical Trial, Clinical Trial, Phase III, Journal Article, Multicenter Study, with publication-date metadata of 2005-10 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16154424-2016-11-24-de7345724055`](#source-pubmed-observation-pmid-16154424-2016-11-24-de7345724055))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16154424-2016-11-24-de7345724055`](#source-pubmed-observation-pmid-16154424-2016-11-24-de7345724055))

### Sources

<a id="source-pubmed-observation-pmid-16154424-2016-11-24-de7345724055"></a>
- **Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. · retained source version 1:2016-11-24:current:de734572405555069515bd20bf569a8f4ab82dab8cdfe697b81e65b01b8cdc07** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16154424/) (`pubmed-observation-pmid-16154424-2016-11-24-de7345724055`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-16154424-lanreotide-v1 SHA-256: 3a9c543d560d1de0d60038497a41ef01f2c981fa25bd809b5020697a76755b2d.

---

<a id="pubmed-pmid-17854356-lanreotide-v1"></a>

## Radiation recall dermatitis in a patient affected with pheochromocytoma after treatment with lanreotide.

> PubMed lists PMID 17854356 in The British journal of dermatology as Case Reports, Letter, with publication-date metadata of 2007-09-13 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17854356-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17854356-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-17854356-lanreotide-v1
- Content SHA-256: `37f76a9977623a9b20f5a0a9eb887264d00202a1fd4233fa4eb4e1e0ff890555`

### Claims and source pins

#### Headline

Radiation recall dermatitis in a patient affected with pheochromocytoma after treatment with lanreotide. ([`pubmed-observation-pmid-17854356-2016-11-24-41f5c924b7a1`](#source-pubmed-observation-pmid-17854356-2016-11-24-41f5c924b7a1))

#### Summary

PubMed lists PMID 17854356 in The British journal of dermatology as Case Reports, Letter, with publication-date metadata of 2007-09-13 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17854356-2016-11-24-41f5c924b7a1`](#source-pubmed-observation-pmid-17854356-2016-11-24-41f5c924b7a1))

#### Paragraph 1

PubMed lists PMID 17854356 in The British journal of dermatology as Case Reports, Letter, with publication-date metadata of 2007-09-13 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17854356-2016-11-24-41f5c924b7a1`](#source-pubmed-observation-pmid-17854356-2016-11-24-41f5c924b7a1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17854356-2016-11-24-41f5c924b7a1`](#source-pubmed-observation-pmid-17854356-2016-11-24-41f5c924b7a1))

### Sources

<a id="source-pubmed-observation-pmid-17854356-2016-11-24-41f5c924b7a1"></a>
- **Radiation recall dermatitis in a patient affected with pheochromocytoma after treatment with lanreotide. · retained source version 1:2016-11-24:current:41f5c924b7a1f84c41e17edc6c5d700a24d57f42069129c82d2ae3ae65c7a91e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17854356/) (`pubmed-observation-pmid-17854356-2016-11-24-41f5c924b7a1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Radiation recall dermatitis in a patient affected with pheochromocytoma after treatment with lanreotide." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-17854356-lanreotide-v1 SHA-256: 37f76a9977623a9b20f5a0a9eb887264d00202a1fd4233fa4eb4e1e0ff890555.

---

<a id="pubmed-pmid-17929329-lanreotide-v1"></a>

## Self-assembly of the octapeptide lanreotide and lanreotide-based derivatives: the role of the aromatic residues.

> PubMed lists PMID 17929329 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008-01 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17929329-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17929329-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-17929329-lanreotide-v1
- Content SHA-256: `6075b5436a86a148c0c425b68973e8ef5cde10ea6e91b8ac49636a30d7391677`

### Claims and source pins

#### Headline

Self-assembly of the octapeptide lanreotide and lanreotide-based derivatives: the role of the aromatic residues. ([`pubmed-observation-pmid-17929329-2016-11-24-5a8e6635b4fc`](#source-pubmed-observation-pmid-17929329-2016-11-24-5a8e6635b4fc))

#### Summary

PubMed lists PMID 17929329 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008-01 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17929329-2016-11-24-5a8e6635b4fc`](#source-pubmed-observation-pmid-17929329-2016-11-24-5a8e6635b4fc))

#### Paragraph 1

PubMed lists PMID 17929329 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008-01 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17929329-2016-11-24-5a8e6635b4fc`](#source-pubmed-observation-pmid-17929329-2016-11-24-5a8e6635b4fc))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17929329-2016-11-24-5a8e6635b4fc`](#source-pubmed-observation-pmid-17929329-2016-11-24-5a8e6635b4fc))

### Sources

<a id="source-pubmed-observation-pmid-17929329-2016-11-24-5a8e6635b4fc"></a>
- **Self-assembly of the octapeptide lanreotide and lanreotide-based derivatives: the role of the aromatic residues. · retained source version 1:2016-11-24:current:5a8e6635b4fc6de6d93dfa013308136a7a3ec12c729fe7071c4666d40bbc6d72** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17929329/) (`pubmed-observation-pmid-17929329-2016-11-24-5a8e6635b4fc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Self-assembly of the octapeptide lanreotide and lanreotide-based derivatives: the role of the aromatic residues." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-17929329-lanreotide-v1 SHA-256: 6075b5436a86a148c0c425b68973e8ef5cde10ea6e91b8ac49636a30d7391677.

---

<a id="pubmed-pmid-17984236-lanreotide-v1"></a>

## Optimalization and cost management of lanreotide-Autogel therapy in acromegaly.

> PubMed lists PMID 17984236 in European journal of endocrinology as Comparative Study, Journal Article, Multicenter Study, with publication-date metadata of 2007-11 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17984236-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17984236-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-17984236-lanreotide-v1
- Content SHA-256: `416cfbfc66d1bf28b71fdf327e898ed6f5c50f1f73cdc9d105b8104210964956`

### Claims and source pins

#### Headline

Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. ([`pubmed-observation-pmid-17984236-2016-11-24-635b9cdf9cc1`](#source-pubmed-observation-pmid-17984236-2016-11-24-635b9cdf9cc1))

#### Summary

PubMed lists PMID 17984236 in European journal of endocrinology as Comparative Study, Journal Article, Multicenter Study, with publication-date metadata of 2007-11 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17984236-2016-11-24-635b9cdf9cc1`](#source-pubmed-observation-pmid-17984236-2016-11-24-635b9cdf9cc1))

#### Paragraph 1

PubMed lists PMID 17984236 in European journal of endocrinology as Comparative Study, Journal Article, Multicenter Study, with publication-date metadata of 2007-11 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17984236-2016-11-24-635b9cdf9cc1`](#source-pubmed-observation-pmid-17984236-2016-11-24-635b9cdf9cc1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17984236-2016-11-24-635b9cdf9cc1`](#source-pubmed-observation-pmid-17984236-2016-11-24-635b9cdf9cc1))

### Sources

<a id="source-pubmed-observation-pmid-17984236-2016-11-24-635b9cdf9cc1"></a>
- **Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. · retained source version 1:2016-11-24:current:635b9cdf9cc133e7bc7ea8702d983def1a91d3e44fcde7fdfc4ee6025676ba6f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17984236/) (`pubmed-observation-pmid-17984236-2016-11-24-635b9cdf9cc1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Optimalization and cost management of lanreotide-Autogel therapy in acromegaly." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-17984236-lanreotide-v1 SHA-256: 416cfbfc66d1bf28b71fdf327e898ed6f5c50f1f73cdc9d105b8104210964956.

---

<a id="pubmed-pmid-18063933-lanreotide-v1"></a>

## Lanreotide autogel and insulin sensitivity markers: report of 5 acromegalic patients and literature review.

> PubMed lists PMID 18063933 in Neuro endocrinology letters as Clinical Trial, Journal Article, Review, with publication-date metadata of 2007-12 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18063933-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18063933-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-18063933-lanreotide-v1
- Content SHA-256: `21e100fc2bf6f8fc90e81a0250c5c5cf300daa06659c4dad3b12ca7a65d27cec`

### Claims and source pins

#### Headline

Lanreotide autogel and insulin sensitivity markers: report of 5 acromegalic patients and literature review. ([`pubmed-observation-pmid-18063933-2016-11-24-25dcdf65b49d`](#source-pubmed-observation-pmid-18063933-2016-11-24-25dcdf65b49d))

#### Summary

PubMed lists PMID 18063933 in Neuro endocrinology letters as Clinical Trial, Journal Article, Review, with publication-date metadata of 2007-12 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18063933-2016-11-24-25dcdf65b49d`](#source-pubmed-observation-pmid-18063933-2016-11-24-25dcdf65b49d))

#### Paragraph 1

PubMed lists PMID 18063933 in Neuro endocrinology letters as Clinical Trial, Journal Article, Review, with publication-date metadata of 2007-12 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18063933-2016-11-24-25dcdf65b49d`](#source-pubmed-observation-pmid-18063933-2016-11-24-25dcdf65b49d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18063933-2016-11-24-25dcdf65b49d`](#source-pubmed-observation-pmid-18063933-2016-11-24-25dcdf65b49d))

### Sources

<a id="source-pubmed-observation-pmid-18063933-2016-11-24-25dcdf65b49d"></a>
- **Lanreotide autogel and insulin sensitivity markers: report of 5 acromegalic patients and literature review. · retained source version 1:2016-11-24:current:25dcdf65b49d6893601141749ebc520a4e27307c2134c9abd8dd9fdd766da966** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18063933/) (`pubmed-observation-pmid-18063933-2016-11-24-25dcdf65b49d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lanreotide autogel and insulin sensitivity markers: report of 5 acromegalic patients and literature review." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-18063933-lanreotide-v1 SHA-256: 21e100fc2bf6f8fc90e81a0250c5c5cf300daa06659c4dad3b12ca7a65d27cec.

---

<a id="pubmed-pmid-18367285-lanreotide-v1"></a>

## Lanreotide Autogel for persistent diabetic macular edema.

> PubMed lists PMID 18367285 in Diabetes research and clinical practice as Case Reports, Journal Article, with publication-date metadata of 2008-03-26 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18367285-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18367285-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-18367285-lanreotide-v1
- Content SHA-256: `3ea7c1b6ee379386df175c5ddfe939787af1185710e127edb4c1f4c5c75b417b`

### Claims and source pins

#### Headline

Lanreotide Autogel for persistent diabetic macular edema. ([`pubmed-observation-pmid-18367285-2016-11-24-4f30b93e4eb9`](#source-pubmed-observation-pmid-18367285-2016-11-24-4f30b93e4eb9))

#### Summary

PubMed lists PMID 18367285 in Diabetes research and clinical practice as Case Reports, Journal Article, with publication-date metadata of 2008-03-26 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18367285-2016-11-24-4f30b93e4eb9`](#source-pubmed-observation-pmid-18367285-2016-11-24-4f30b93e4eb9))

#### Paragraph 1

PubMed lists PMID 18367285 in Diabetes research and clinical practice as Case Reports, Journal Article, with publication-date metadata of 2008-03-26 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18367285-2016-11-24-4f30b93e4eb9`](#source-pubmed-observation-pmid-18367285-2016-11-24-4f30b93e4eb9))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18367285-2016-11-24-4f30b93e4eb9`](#source-pubmed-observation-pmid-18367285-2016-11-24-4f30b93e4eb9))

### Sources

<a id="source-pubmed-observation-pmid-18367285-2016-11-24-4f30b93e4eb9"></a>
- **Lanreotide Autogel for persistent diabetic macular edema. · retained source version 1:2016-11-24:current:4f30b93e4eb99070c75306400e4ab9a950610c47a7e7be896061dbc9340657c2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18367285/) (`pubmed-observation-pmid-18367285-2016-11-24-4f30b93e4eb9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lanreotide Autogel for persistent diabetic macular edema." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-18367285-lanreotide-v1 SHA-256: 3ea7c1b6ee379386df175c5ddfe939787af1185710e127edb4c1f4c5c75b417b.

---

<a id="pubmed-pmid-18684551-lanreotide-v1"></a>

## Para-aortic lymphocele treated with an injection of somatostatine analog (lanreotide).

> PubMed lists PMID 18684551 in European journal of obstetrics, gynecology, and reproductive biology as Case Reports, Letter, with publication-date metadata of 2008-08-05 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18684551-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18684551-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-18684551-lanreotide-v1
- Content SHA-256: `42a7272a18ec08afdca311675e1eea14136915c170b6ab132e5072dc9746335d`

### Claims and source pins

#### Headline

Para-aortic lymphocele treated with an injection of somatostatine analog (lanreotide). ([`pubmed-observation-pmid-18684551-2016-11-24-f00668d1cea1`](#source-pubmed-observation-pmid-18684551-2016-11-24-f00668d1cea1))

#### Summary

PubMed lists PMID 18684551 in European journal of obstetrics, gynecology, and reproductive biology as Case Reports, Letter, with publication-date metadata of 2008-08-05 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18684551-2016-11-24-f00668d1cea1`](#source-pubmed-observation-pmid-18684551-2016-11-24-f00668d1cea1))

#### Paragraph 1

PubMed lists PMID 18684551 in European journal of obstetrics, gynecology, and reproductive biology as Case Reports, Letter, with publication-date metadata of 2008-08-05 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18684551-2016-11-24-f00668d1cea1`](#source-pubmed-observation-pmid-18684551-2016-11-24-f00668d1cea1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18684551-2016-11-24-f00668d1cea1`](#source-pubmed-observation-pmid-18684551-2016-11-24-f00668d1cea1))

### Sources

<a id="source-pubmed-observation-pmid-18684551-2016-11-24-f00668d1cea1"></a>
- **Para-aortic lymphocele treated with an injection of somatostatine analog (lanreotide). · retained source version 1:2016-11-24:current:f00668d1cea11b16c76c7065f9b57f9e57a3ab91ba9651eda1d2ff6fa6219be6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18684551/) (`pubmed-observation-pmid-18684551-2016-11-24-f00668d1cea1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Para-aortic lymphocele treated with an injection of somatostatine analog (lanreotide)." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-18684551-lanreotide-v1 SHA-256: 42a7272a18ec08afdca311675e1eea14136915c170b6ab132e5072dc9746335d.

---

<a id="pubmed-pmid-19258715-lanreotide-v1"></a>

## Long-acting lanreotide in adolescent girls with constitutional tall stature.

> PubMed lists PMID 19258715 in Hormone research as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 2009-03-04 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-19258715-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-19258715-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-19258715-lanreotide-v1
- Content SHA-256: `71652fcf3310b082fdbffc64f7a8953e2134ef2d1aded7079e923bbffe3db159`

### Claims and source pins

#### Headline

Long-acting lanreotide in adolescent girls with constitutional tall stature. ([`pubmed-observation-pmid-19258715-2016-11-25-31d2a1eebfa9`](#source-pubmed-observation-pmid-19258715-2016-11-25-31d2a1eebfa9))

#### Summary

PubMed lists PMID 19258715 in Hormone research as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 2009-03-04 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19258715-2016-11-25-31d2a1eebfa9`](#source-pubmed-observation-pmid-19258715-2016-11-25-31d2a1eebfa9))

#### Paragraph 1

PubMed lists PMID 19258715 in Hormone research as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 2009-03-04 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19258715-2016-11-25-31d2a1eebfa9`](#source-pubmed-observation-pmid-19258715-2016-11-25-31d2a1eebfa9))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-19258715-2016-11-25-31d2a1eebfa9`](#source-pubmed-observation-pmid-19258715-2016-11-25-31d2a1eebfa9))

### Sources

<a id="source-pubmed-observation-pmid-19258715-2016-11-25-31d2a1eebfa9"></a>
- **Long-acting lanreotide in adolescent girls with constitutional tall stature. · retained source version 1:2016-11-25:current:31d2a1eebfa99d0c52a97869cf6d8441594d3841074e3b5a9b720b54b7cc347b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/19258715/) (`pubmed-observation-pmid-19258715-2016-11-25-31d2a1eebfa9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Long-acting lanreotide in adolescent girls with constitutional tall stature." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-19258715-lanreotide-v1 SHA-256: 71652fcf3310b082fdbffc64f7a8953e2134ef2d1aded7079e923bbffe3db159.

---

<a id="pubmed-pmid-20168286-lanreotide-v1"></a>

## Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.

> PubMed lists PMID 20168286 in The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) \[and\] the International Association of Radiopharmacology (IAR), \[and\] Section of the Society of... as Clinical Trial, Journal Article, with publication-date metadata of 2010-02 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20168286-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20168286-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-20168286-lanreotide-v1
- Content SHA-256: `ad852929649a33c3ed54d8fbe6af4b170cf87fdbe16457e294808a019e008ed0`

### Claims and source pins

#### Headline

Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography. ([`pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869`](#source-pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869))

#### Summary

PubMed lists PMID 20168286 in The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) \[and\] the International Association of Radiopharmacology (IAR), \[and\] Section of the Society of... as Clinical Trial, Journal Article, with publication-date metadata of 2010-02 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869`](#source-pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869))

#### Paragraph 1

PubMed lists PMID 20168286 in The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) \[and\] the International Association of Radiopharmacology (IAR), \[and\] Section of the Society of... as Clinical Trial, Journal Article, with publication-date metadata of 2010-02 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869`](#source-pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869`](#source-pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869))

### Sources

<a id="source-pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869"></a>
- **Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography. · retained source version 1:2016-11-25:current:d1ab9efa1869c48145852bbef1f2dde7fa559213e4a6dcbd278c26e3c2197c94** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20168286/) (`pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-20168286-lanreotide-v1 SHA-256: ad852929649a33c3ed54d8fbe6af4b170cf87fdbe16457e294808a019e008ed0.

---

<a id="pubmed-pmid-20199027-lanreotide-v1"></a>

## Elucidation of the self-assembly pathway of lanreotide octapeptide into beta-sheet nanotubes: role of two stable intermediates.

> PubMed lists PMID 20199027 in Journal of the American Chemical Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-03-31 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20199027-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20199027-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-20199027-lanreotide-v1
- Content SHA-256: `5f29580a46b691a0844869863ad4c219390c4e6bb409b57fbea3401555185850`

### Claims and source pins

#### Headline

Elucidation of the self-assembly pathway of lanreotide octapeptide into beta-sheet nanotubes: role of two stable intermediates. ([`pubmed-observation-pmid-20199027-2016-11-25-204f8be609c7`](#source-pubmed-observation-pmid-20199027-2016-11-25-204f8be609c7))

#### Summary

PubMed lists PMID 20199027 in Journal of the American Chemical Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-03-31 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20199027-2016-11-25-204f8be609c7`](#source-pubmed-observation-pmid-20199027-2016-11-25-204f8be609c7))

#### Paragraph 1

PubMed lists PMID 20199027 in Journal of the American Chemical Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-03-31 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20199027-2016-11-25-204f8be609c7`](#source-pubmed-observation-pmid-20199027-2016-11-25-204f8be609c7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20199027-2016-11-25-204f8be609c7`](#source-pubmed-observation-pmid-20199027-2016-11-25-204f8be609c7))

### Sources

<a id="source-pubmed-observation-pmid-20199027-2016-11-25-204f8be609c7"></a>
- **Elucidation of the self-assembly pathway of lanreotide octapeptide into beta-sheet nanotubes: role of two stable intermediates. · retained source version 1:2016-11-25:current:204f8be609c71c6052ba5d93486cec2bb7cd2ca074b9c2883339a8234b584892** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20199027/) (`pubmed-observation-pmid-20199027-2016-11-25-204f8be609c7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Elucidation of the self-assembly pathway of lanreotide octapeptide into beta-sheet nanotubes: role of two stable intermediates." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-20199027-lanreotide-v1 SHA-256: 5f29580a46b691a0844869863ad4c219390c4e6bb409b57fbea3401555185850.

---

<a id="pubmed-pmid-20604834-lanreotide-v1"></a>

## Therapeutic 188Re-lanreotide: determination of radiopharmacokinetic parameters in rats.

> PubMed lists PMID 20604834 in The Journal of pharmacy and pharmacology as Journal Article, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20604834-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20604834-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-20604834-lanreotide-v1
- Content SHA-256: `b52b7c2e734a63cf011e3268e3a31c9648b1c06284fdd2b3dabffaa3682caa5d`

### Claims and source pins

#### Headline

Therapeutic 188Re-lanreotide: determination of radiopharmacokinetic parameters in rats. ([`pubmed-observation-pmid-20604834-2016-11-25-695da1512200`](#source-pubmed-observation-pmid-20604834-2016-11-25-695da1512200))

#### Summary

PubMed lists PMID 20604834 in The Journal of pharmacy and pharmacology as Journal Article, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20604834-2016-11-25-695da1512200`](#source-pubmed-observation-pmid-20604834-2016-11-25-695da1512200))

#### Paragraph 1

PubMed lists PMID 20604834 in The Journal of pharmacy and pharmacology as Journal Article, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20604834-2016-11-25-695da1512200`](#source-pubmed-observation-pmid-20604834-2016-11-25-695da1512200))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20604834-2016-11-25-695da1512200`](#source-pubmed-observation-pmid-20604834-2016-11-25-695da1512200))

### Sources

<a id="source-pubmed-observation-pmid-20604834-2016-11-25-695da1512200"></a>
- **Therapeutic 188Re-lanreotide: determination of radiopharmacokinetic parameters in rats. · retained source version 1:2016-11-25:current:695da151220066cdbfe3d0b90f22a4c1ea7783871cba56aad6e8c6dcb80f95b1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20604834/) (`pubmed-observation-pmid-20604834-2016-11-25-695da1512200`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Therapeutic 188Re-lanreotide: determination of radiopharmacokinetic parameters in rats." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-20604834-lanreotide-v1 SHA-256: b52b7c2e734a63cf011e3268e3a31c9648b1c06284fdd2b3dabffaa3682caa5d.

---

<a id="pubmed-pmid-21135689-lanreotide-v1"></a>

## Use of lanreotide for the treatment of gastrointestinal fistulae.

> PubMed lists PMID 21135689 in Annals of surgery as Letter, Comment, with publication-date metadata of 2011-01 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-21135689-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-21135689-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-21135689-lanreotide-v1
- Content SHA-256: `d24f1ae9bf69e72785180c6ceb7e233300c1151c4494a1343765467b9e730992`

### Claims and source pins

#### Headline

Use of lanreotide for the treatment of gastrointestinal fistulae. ([`pubmed-observation-pmid-21135689-2016-11-25-1cfb22a9d387`](#source-pubmed-observation-pmid-21135689-2016-11-25-1cfb22a9d387))

#### Summary

PubMed lists PMID 21135689 in Annals of surgery as Letter, Comment, with publication-date metadata of 2011-01 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-21135689-2016-11-25-1cfb22a9d387`](#source-pubmed-observation-pmid-21135689-2016-11-25-1cfb22a9d387))

#### Paragraph 1

PubMed lists PMID 21135689 in Annals of surgery as Letter, Comment, with publication-date metadata of 2011-01 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-21135689-2016-11-25-1cfb22a9d387`](#source-pubmed-observation-pmid-21135689-2016-11-25-1cfb22a9d387))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-21135689-2016-11-25-1cfb22a9d387`](#source-pubmed-observation-pmid-21135689-2016-11-25-1cfb22a9d387))

### Sources

<a id="source-pubmed-observation-pmid-21135689-2016-11-25-1cfb22a9d387"></a>
- **Use of lanreotide for the treatment of gastrointestinal fistulae. · retained source version 1:2016-11-25:current:1cfb22a9d3870b7e907b6c3480a09dd7e6742cf8575e41228be2f61f4790dd9c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/21135689/) (`pubmed-observation-pmid-21135689-2016-11-25-1cfb22a9d387`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Use of lanreotide for the treatment of gastrointestinal fistulae." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-21135689-lanreotide-v1 SHA-256: d24f1ae9bf69e72785180c6ceb7e233300c1151c4494a1343765467b9e730992.

---

<a id="pubmed-pmid-21607321-lanreotide-v1"></a>

## PubMed record PMID 21607321

> PeptideScanner retained PubMed bibliographic metadata for PMID 21607321 at 2026-07-30T22:17:00.088Z. PubMed recorded a metadata revision date of 2011-05-24 and an Entrez history date of 2011-05-25. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-21607321-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2011-05-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-21607321-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-21607321-lanreotide-v1
- Content SHA-256: `5135c29d97a163780f4cab9f18be6b1d9260f76e454de03447206634ddb4dfb5`

### Claims and source pins

#### Headline

PubMed record PMID 21607321 ([`pubmed-observation-pmid-21607321-2011-05-24-2eb5bea25f63`](#source-pubmed-observation-pmid-21607321-2011-05-24-2eb5bea25f63))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 21607321 at 2026-07-30T22:17:00.088Z. PubMed recorded a metadata revision date of 2011-05-24 and an Entrez history date of 2011-05-25. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-21607321-2011-05-24-2eb5bea25f63`](#source-pubmed-observation-pmid-21607321-2011-05-24-2eb5bea25f63))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 21607321 at 2026-07-30T22:17:00.088Z. PubMed recorded a metadata revision date of 2011-05-24 and an Entrez history date of 2011-05-25. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-21607321-2011-05-24-2eb5bea25f63`](#source-pubmed-observation-pmid-21607321-2011-05-24-2eb5bea25f63))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-21607321-2011-05-24-2eb5bea25f63`](#source-pubmed-observation-pmid-21607321-2011-05-24-2eb5bea25f63))

### Sources

<a id="source-pubmed-observation-pmid-21607321-2011-05-24-2eb5bea25f63"></a>
- **PubMed record PMID 21607321 · retained source version 1:2011-05-24:current:2eb5bea25f637392910c1ceee3a2a8c6ccfac922a789fc8d83ccc9296fd58a45** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/21607321/) (`pubmed-observation-pmid-21607321-2011-05-24-2eb5bea25f63`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 21607321." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-21607321-lanreotide-v1 SHA-256: 5135c29d97a163780f4cab9f18be6b1d9260f76e454de03447206634ddb4dfb5.

---

<a id="pubmed-pmid-25682623-lanreotide-v1"></a>

## Resolving bile reflux by lanreotide in patients with Roux-en-Y gastrojejunostomy.

> PubMed lists PMID 25682623 in Acta gastro-enterologica Belgica as Case Reports, Journal Article, with publication-date metadata of 2014-12 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-25682623-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25682623-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-25682623-lanreotide-v1
- Content SHA-256: `4cd8f191587e12285dc18b384dc4e1afae92b660565c14bf6b93fb515bd3e05e`

### Claims and source pins

#### Headline

Resolving bile reflux by lanreotide in patients with Roux-en-Y gastrojejunostomy. ([`pubmed-observation-pmid-25682623-2016-11-25-3b8876273c12`](#source-pubmed-observation-pmid-25682623-2016-11-25-3b8876273c12))

#### Summary

PubMed lists PMID 25682623 in Acta gastro-enterologica Belgica as Case Reports, Journal Article, with publication-date metadata of 2014-12 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25682623-2016-11-25-3b8876273c12`](#source-pubmed-observation-pmid-25682623-2016-11-25-3b8876273c12))

#### Paragraph 1

PubMed lists PMID 25682623 in Acta gastro-enterologica Belgica as Case Reports, Journal Article, with publication-date metadata of 2014-12 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25682623-2016-11-25-3b8876273c12`](#source-pubmed-observation-pmid-25682623-2016-11-25-3b8876273c12))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25682623-2016-11-25-3b8876273c12`](#source-pubmed-observation-pmid-25682623-2016-11-25-3b8876273c12))

### Sources

<a id="source-pubmed-observation-pmid-25682623-2016-11-25-3b8876273c12"></a>
- **Resolving bile reflux by lanreotide in patients with Roux-en-Y gastrojejunostomy. · retained source version 1:2016-11-25:current:3b8876273c12a6d08cc0986b7b690557871d063c3aef043e774b3fd53362c4d3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25682623/) (`pubmed-observation-pmid-25682623-2016-11-25-3b8876273c12`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Resolving bile reflux by lanreotide in patients with Roux-en-Y gastrojejunostomy." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-25682623-lanreotide-v1 SHA-256: 4cd8f191587e12285dc18b384dc4e1afae92b660565c14bf6b93fb515bd3e05e.

---

<a id="pubmed-pmid-25746137-lanreotide-v1"></a>

## Combinative treatment of transarterial chemoembolization, celecoxib and lanreotide in unresectable hepatocellular carcinoma.

> PubMed lists PMID 25746137 in Clinics and research in hepatology and gastroenterology as Case Reports, Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-03-04 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-25746137-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25746137-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-25746137-lanreotide-v1
- Content SHA-256: `a30568ea040f1fbf1ffccb0452c81f758af384463f9b001f7d43feb35ee8932b`

### Claims and source pins

#### Headline

Combinative treatment of transarterial chemoembolization, celecoxib and lanreotide in unresectable hepatocellular carcinoma. ([`pubmed-observation-pmid-25746137-2016-11-25-dc806b43134c`](#source-pubmed-observation-pmid-25746137-2016-11-25-dc806b43134c))

#### Summary

PubMed lists PMID 25746137 in Clinics and research in hepatology and gastroenterology as Case Reports, Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-03-04 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25746137-2016-11-25-dc806b43134c`](#source-pubmed-observation-pmid-25746137-2016-11-25-dc806b43134c))

#### Paragraph 1

PubMed lists PMID 25746137 in Clinics and research in hepatology and gastroenterology as Case Reports, Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-03-04 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25746137-2016-11-25-dc806b43134c`](#source-pubmed-observation-pmid-25746137-2016-11-25-dc806b43134c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25746137-2016-11-25-dc806b43134c`](#source-pubmed-observation-pmid-25746137-2016-11-25-dc806b43134c))

### Sources

<a id="source-pubmed-observation-pmid-25746137-2016-11-25-dc806b43134c"></a>
- **Combinative treatment of transarterial chemoembolization, celecoxib and lanreotide in unresectable hepatocellular carcinoma. · retained source version 1:2016-11-25:current:dc806b43134ceedf35151775ed56fb728d132411edb1e65904dccfdba61d2dff** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25746137/) (`pubmed-observation-pmid-25746137-2016-11-25-dc806b43134c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Combinative treatment of transarterial chemoembolization, celecoxib and lanreotide in unresectable hepatocellular carcinoma." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-25746137-lanreotide-v1 SHA-256: a30568ea040f1fbf1ffccb0452c81f758af384463f9b001f7d43feb35ee8932b.

---

<a id="pubmed-pmid-27200668-lanreotide-v1"></a>

## PubMed record PMID 27200668

> PeptideScanner retained PubMed bibliographic metadata for PMID 27200668 at 2026-07-30T21:38:23.145Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-27200668-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-05-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27200668-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-27200668-lanreotide-v1
- Content SHA-256: `1614c605395705888e9153f43dbdd0f1f27cb873dd12c88b6488a6361d0d34d2`

### Claims and source pins

#### Headline

PubMed record PMID 27200668 ([`pubmed-observation-pmid-27200668-2016-05-21-b66ad3598663`](#source-pubmed-observation-pmid-27200668-2016-05-21-b66ad3598663))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 27200668 at 2026-07-30T21:38:23.145Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27200668-2016-05-21-b66ad3598663`](#source-pubmed-observation-pmid-27200668-2016-05-21-b66ad3598663))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 27200668 at 2026-07-30T21:38:23.145Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27200668-2016-05-21-b66ad3598663`](#source-pubmed-observation-pmid-27200668-2016-05-21-b66ad3598663))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27200668-2016-05-21-b66ad3598663`](#source-pubmed-observation-pmid-27200668-2016-05-21-b66ad3598663))

### Sources

<a id="source-pubmed-observation-pmid-27200668-2016-05-21-b66ad3598663"></a>
- **PubMed record PMID 27200668 · retained source version 1:2016-05-21:current:b66ad359866312b381f1d0b589ef3983a83aa82caf8c9500dbaec1c06a0ed3af** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27200668/) (`pubmed-observation-pmid-27200668-2016-05-21-b66ad3598663`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 27200668." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-27200668-lanreotide-v1 SHA-256: 1614c605395705888e9153f43dbdd0f1f27cb873dd12c88b6488a6361d0d34d2.

---

<a id="pubmed-pmid-38071418-lanreotide-v1"></a>

## PubMed record PMID 38071418

> PeptideScanner retained PubMed bibliographic metadata for PMID 38071418 at 2026-07-30T16:20:36.586Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2023-12-10. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-38071418-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38071418-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-38071418-lanreotide-v1
- Content SHA-256: `82b8817a789c751337277aef4f941b53825dbe889792e9d86593565e6f4eee01`

### Claims and source pins

#### Headline

PubMed record PMID 38071418 ([`pubmed-observation-pmid-38071418-2026-05-18-74e17d2115b4`](#source-pubmed-observation-pmid-38071418-2026-05-18-74e17d2115b4))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 38071418 at 2026-07-30T16:20:36.586Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2023-12-10. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38071418-2026-05-18-74e17d2115b4`](#source-pubmed-observation-pmid-38071418-2026-05-18-74e17d2115b4))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 38071418 at 2026-07-30T16:20:36.586Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2023-12-10. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38071418-2026-05-18-74e17d2115b4`](#source-pubmed-observation-pmid-38071418-2026-05-18-74e17d2115b4))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38071418-2026-05-18-74e17d2115b4`](#source-pubmed-observation-pmid-38071418-2026-05-18-74e17d2115b4))

### Sources

<a id="source-pubmed-observation-pmid-38071418-2026-05-18-74e17d2115b4"></a>
- **PubMed record PMID 38071418 · retained source version 1:2026-05-18:current:74e17d2115b41b266d6c32bc6d9cb69b6f68a0a411567765a2626efe1fd0d05f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38071418/) (`pubmed-observation-pmid-38071418-2026-05-18-74e17d2115b4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 38071418." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-38071418-lanreotide-v1 SHA-256: 82b8817a789c751337277aef4f941b53825dbe889792e9d86593565e6f4eee01.

---

<a id="pubmed-pmid-38206830-lanreotide-v1"></a>

## Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.

> PubMed lists PMID 38206830 in The oncologist as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2024-05-03 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38206830-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-04-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38206830-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-38206830-lanreotide-v1
- Content SHA-256: `63ba7cfc07091c3d999640bf70cea20cc2525a6314162556ceff4148b5f03359`

### Claims and source pins

#### Headline

Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study. ([`pubmed-observation-pmid-38206830-2026-04-30-9a3b7f34f72a`](#source-pubmed-observation-pmid-38206830-2026-04-30-9a3b7f34f72a))

#### Summary

PubMed lists PMID 38206830 in The oncologist as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2024-05-03 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38206830-2026-04-30-9a3b7f34f72a`](#source-pubmed-observation-pmid-38206830-2026-04-30-9a3b7f34f72a))

#### Paragraph 1

PubMed lists PMID 38206830 in The oncologist as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2024-05-03 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38206830-2026-04-30-9a3b7f34f72a`](#source-pubmed-observation-pmid-38206830-2026-04-30-9a3b7f34f72a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38206830-2026-04-30-9a3b7f34f72a`](#source-pubmed-observation-pmid-38206830-2026-04-30-9a3b7f34f72a))

### Sources

<a id="source-pubmed-observation-pmid-38206830-2026-04-30-9a3b7f34f72a"></a>
- **Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study. · retained source version 1:2026-04-30:current:9a3b7f34f72ae55a13b9d614daf28e593d472ad01713bf8234b958ee2d57ad5d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38206830/) (`pubmed-observation-pmid-38206830-2026-04-30-9a3b7f34f72a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-38206830-lanreotide-v1 SHA-256: 63ba7cfc07091c3d999640bf70cea20cc2525a6314162556ceff4148b5f03359.

---

<a id="pubmed-pmid-39491674-lanreotide-v1"></a>

## β-Cyclodextrin derivatives bind aromatic side chains of the cyclic peptide lanreotide.

> PubMed lists PMID 39491674 in Journal of pharmaceutical sciences as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-11-02 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39491674-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39491674-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-39491674-lanreotide-v1
- Content SHA-256: `8a694417089e35a2306c23cbb20066dd714d291e21fbbccb62f5c12213971f74`

### Claims and source pins

#### Headline

β-Cyclodextrin derivatives bind aromatic side chains of the cyclic peptide lanreotide. ([`pubmed-observation-pmid-39491674-2026-05-17-2f1f823680fc`](#source-pubmed-observation-pmid-39491674-2026-05-17-2f1f823680fc))

#### Summary

PubMed lists PMID 39491674 in Journal of pharmaceutical sciences as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-11-02 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39491674-2026-05-17-2f1f823680fc`](#source-pubmed-observation-pmid-39491674-2026-05-17-2f1f823680fc))

#### Paragraph 1

PubMed lists PMID 39491674 in Journal of pharmaceutical sciences as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-11-02 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39491674-2026-05-17-2f1f823680fc`](#source-pubmed-observation-pmid-39491674-2026-05-17-2f1f823680fc))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39491674-2026-05-17-2f1f823680fc`](#source-pubmed-observation-pmid-39491674-2026-05-17-2f1f823680fc))

### Sources

<a id="source-pubmed-observation-pmid-39491674-2026-05-17-2f1f823680fc"></a>
- **β-Cyclodextrin derivatives bind aromatic side chains of the cyclic peptide lanreotide. · retained source version 1:2026-05-17:current:2f1f823680fcb8de0f2d773287c3601a31267253146e281c68f7ccfde6c15a00** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39491674/) (`pubmed-observation-pmid-39491674-2026-05-17-2f1f823680fc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "β-Cyclodextrin derivatives bind aromatic side chains of the cyclic peptide lanreotide." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-39491674-lanreotide-v1 SHA-256: 8a694417089e35a2306c23cbb20066dd714d291e21fbbccb62f5c12213971f74.

---

<a id="pubmed-pmid-39933708-lanreotide-v1"></a>

## PubMed record PMID 39933708

> PeptideScanner retained PubMed bibliographic metadata for PMID 39933708 at 2026-07-30T16:14:10.854Z. PubMed recorded a metadata revision date of 2026-06-09 and an Entrez history date of 2025-02-11. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-39933708-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39933708-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-39933708-lanreotide-v1
- Content SHA-256: `273dbb299084238f7740ae1d638ff7857babd9a6a26da44b8bc2474903308796`

### Claims and source pins

#### Headline

PubMed record PMID 39933708 ([`pubmed-observation-pmid-39933708-2026-06-09-66fec74eaed4`](#source-pubmed-observation-pmid-39933708-2026-06-09-66fec74eaed4))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 39933708 at 2026-07-30T16:14:10.854Z. PubMed recorded a metadata revision date of 2026-06-09 and an Entrez history date of 2025-02-11. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39933708-2026-06-09-66fec74eaed4`](#source-pubmed-observation-pmid-39933708-2026-06-09-66fec74eaed4))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 39933708 at 2026-07-30T16:14:10.854Z. PubMed recorded a metadata revision date of 2026-06-09 and an Entrez history date of 2025-02-11. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39933708-2026-06-09-66fec74eaed4`](#source-pubmed-observation-pmid-39933708-2026-06-09-66fec74eaed4))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39933708-2026-06-09-66fec74eaed4`](#source-pubmed-observation-pmid-39933708-2026-06-09-66fec74eaed4))

### Sources

<a id="source-pubmed-observation-pmid-39933708-2026-06-09-66fec74eaed4"></a>
- **PubMed record PMID 39933708 · retained source version 1:2026-06-09:current:66fec74eaed402b22faffb8054f34d32687fb7c06e3febc03651189e55d4aa88** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39933708/) (`pubmed-observation-pmid-39933708-2026-06-09-66fec74eaed4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 39933708." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-39933708-lanreotide-v1 SHA-256: 273dbb299084238f7740ae1d638ff7857babd9a6a26da44b8bc2474903308796.

---

<a id="pubmed-pmid-41071230-lanreotide-v1"></a>

## Lanreotide in endothelial corneal inflammation.

> PubMed lists PMID 41071230 in Hormones (Athens, Greece) as Letter, with publication-date metadata of 2025-10-10 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41071230-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-03-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41071230-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-41071230-lanreotide-v1
- Content SHA-256: `5a070841444d7f3bf8a2dbf8d6227fb3d6455b0b9d2d8770a9c620a0037a76ce`

### Claims and source pins

#### Headline

Lanreotide in endothelial corneal inflammation. ([`pubmed-observation-pmid-41071230-2026-03-25-a4ce3d1a2dbb`](#source-pubmed-observation-pmid-41071230-2026-03-25-a4ce3d1a2dbb))

#### Summary

PubMed lists PMID 41071230 in Hormones (Athens, Greece) as Letter, with publication-date metadata of 2025-10-10 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41071230-2026-03-25-a4ce3d1a2dbb`](#source-pubmed-observation-pmid-41071230-2026-03-25-a4ce3d1a2dbb))

#### Paragraph 1

PubMed lists PMID 41071230 in Hormones (Athens, Greece) as Letter, with publication-date metadata of 2025-10-10 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41071230-2026-03-25-a4ce3d1a2dbb`](#source-pubmed-observation-pmid-41071230-2026-03-25-a4ce3d1a2dbb))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41071230-2026-03-25-a4ce3d1a2dbb`](#source-pubmed-observation-pmid-41071230-2026-03-25-a4ce3d1a2dbb))

### Sources

<a id="source-pubmed-observation-pmid-41071230-2026-03-25-a4ce3d1a2dbb"></a>
- **Lanreotide in endothelial corneal inflammation. · retained source version 1:2026-03-25:current:a4ce3d1a2dbbb3d55f7922623629a063ca8894c59c34cdb0e9d9cc10d4ede6bd** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41071230/) (`pubmed-observation-pmid-41071230-2026-03-25-a4ce3d1a2dbb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lanreotide in endothelial corneal inflammation." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-41071230-lanreotide-v1 SHA-256: 5a070841444d7f3bf8a2dbf8d6227fb3d6455b0b9d2d8770a9c620a0037a76ce.

---

<a id="pubmed-pmid-41880072-lanreotide-v1"></a>

## PubMed record PMID 41880072

> PeptideScanner retained PubMed bibliographic metadata for PMID 41880072 at 2026-07-30T16:14:14.928Z. PubMed recorded a metadata revision date of 2026-06-27 and an Entrez history date of 2026-03-25. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41880072-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41880072-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-41880072-lanreotide-v1
- Content SHA-256: `795ffd0cf18c3324d4ef5bf3b9898aef2c135c84009656bc04e530fe3cfbeb72`

### Claims and source pins

#### Headline

PubMed record PMID 41880072 ([`pubmed-observation-pmid-41880072-2026-06-27-12975518d046`](#source-pubmed-observation-pmid-41880072-2026-06-27-12975518d046))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41880072 at 2026-07-30T16:14:14.928Z. PubMed recorded a metadata revision date of 2026-06-27 and an Entrez history date of 2026-03-25. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41880072-2026-06-27-12975518d046`](#source-pubmed-observation-pmid-41880072-2026-06-27-12975518d046))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41880072 at 2026-07-30T16:14:14.928Z. PubMed recorded a metadata revision date of 2026-06-27 and an Entrez history date of 2026-03-25. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41880072-2026-06-27-12975518d046`](#source-pubmed-observation-pmid-41880072-2026-06-27-12975518d046))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41880072-2026-06-27-12975518d046`](#source-pubmed-observation-pmid-41880072-2026-06-27-12975518d046))

### Sources

<a id="source-pubmed-observation-pmid-41880072-2026-06-27-12975518d046"></a>
- **PubMed record PMID 41880072 · retained source version 1:2026-06-27:current:12975518d046b255d866948fba51a8c0e50030f7230515c78a2afc4b58997435** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41880072/) (`pubmed-observation-pmid-41880072-2026-06-27-12975518d046`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41880072." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-41880072-lanreotide-v1 SHA-256: 795ffd0cf18c3324d4ef5bf3b9898aef2c135c84009656bc04e530fe3cfbeb72.

---

<a id="pubmed-pmid-42721062-lanreotide-v1"></a>

## Pregnancy in a patient with metastatic functioning midgut neuroendocrine tumor receiving lanreotide after peptide receptor radionuclide therapy.

> PubMed lists PMID 42721062 in Archives of endocrinology and metabolism as Case Reports, Journal Article, with publication-date metadata of 2026-09-10 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42721062-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-21
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42721062-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-42721062-lanreotide-v1
- Content SHA-256: `2bed81cac80620fc6d02a03f875aaaaec12b39938417845f1d44ef8afd5ab265`

### Claims and source pins

#### Headline

Pregnancy in a patient with metastatic functioning midgut neuroendocrine tumor receiving lanreotide after peptide receptor radionuclide therapy. ([`pubmed-observation-pmid-42721062-2026-09-21-5b1b4aab5391`](#source-pubmed-observation-pmid-42721062-2026-09-21-5b1b4aab5391))

#### Summary

PubMed lists PMID 42721062 in Archives of endocrinology and metabolism as Case Reports, Journal Article, with publication-date metadata of 2026-09-10 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42721062-2026-09-21-5b1b4aab5391`](#source-pubmed-observation-pmid-42721062-2026-09-21-5b1b4aab5391))

#### Paragraph 1

PubMed lists PMID 42721062 in Archives of endocrinology and metabolism as Case Reports, Journal Article, with publication-date metadata of 2026-09-10 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42721062-2026-09-21-5b1b4aab5391`](#source-pubmed-observation-pmid-42721062-2026-09-21-5b1b4aab5391))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42721062-2026-09-21-5b1b4aab5391`](#source-pubmed-observation-pmid-42721062-2026-09-21-5b1b4aab5391))

### Sources

<a id="source-pubmed-observation-pmid-42721062-2026-09-21-5b1b4aab5391"></a>
- **Pregnancy in a patient with metastatic functioning midgut neuroendocrine tumor receiving lanreotide after peptide receptor radionuclide therapy. · retained source version 1:2026-09-21:current:5b1b4aab539131c0db64d6d2f18a0e26c44a3a3e5d995e1a898fd8f8c53b4bdd** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42721062/) (`pubmed-observation-pmid-42721062-2026-09-21-5b1b4aab5391`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pregnancy in a patient with metastatic functioning midgut neuroendocrine tumor receiving lanreotide after peptide receptor radionuclide therapy." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-42721062-lanreotide-v1 SHA-256: 2bed81cac80620fc6d02a03f875aaaaec12b39938417845f1d44ef8afd5ab265.

---

<a id="pubmed-pmid-42791653-lanreotide-v1"></a>

## Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study.

> PubMed lists PMID 42791653 in Cancer medicine as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2026-10 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42791653-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-30
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42791653-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-42791653-lanreotide-v1
- Content SHA-256: `942f202901b1f488903efebfc398c444f389c8f6635969b69a8bfb5129c6f4b3`

### Claims and source pins

#### Headline

Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study. ([`pubmed-observation-pmid-42791653-2026-09-30-720ad5b64a72`](#source-pubmed-observation-pmid-42791653-2026-09-30-720ad5b64a72))

#### Summary

PubMed lists PMID 42791653 in Cancer medicine as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2026-10 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42791653-2026-09-30-720ad5b64a72`](#source-pubmed-observation-pmid-42791653-2026-09-30-720ad5b64a72))

#### Paragraph 1

PubMed lists PMID 42791653 in Cancer medicine as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2026-10 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42791653-2026-09-30-720ad5b64a72`](#source-pubmed-observation-pmid-42791653-2026-09-30-720ad5b64a72))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42791653-2026-09-30-720ad5b64a72`](#source-pubmed-observation-pmid-42791653-2026-09-30-720ad5b64a72))

### Sources

<a id="source-pubmed-observation-pmid-42791653-2026-09-30-720ad5b64a72"></a>
- **Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study. · retained source version 1:2026-09-30:current:720ad5b64a72166abf418e1673c8df3f76a1b3c37ba488c6d1d3d1ff1acda781** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42791653/) (`pubmed-observation-pmid-42791653-2026-09-30-720ad5b64a72`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-42791653-lanreotide-v1 SHA-256: 942f202901b1f488903efebfc398c444f389c8f6635969b69a8bfb5129c6f4b3.

---

<a id="pubmed-pmid-42976416-lanreotide-v1"></a>

## A phase I/II study using cabozantinib and lanreotide as treatments for advanced GEP-NETs for which molecular targeted therapy or chemotherapy have failed (SCALET): TCOG T2221 study.

> PubMed lists PMID 42976416 in ESMO open as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42976416-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-13
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42976416-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-42976416-lanreotide-v1
- Content SHA-256: `709560d6d4c211f14a192764612212d368a46a188729e2c0f5f4cd0ce4d14d9e`

### Claims and source pins

#### Headline

A phase I/II study using cabozantinib and lanreotide as treatments for advanced GEP-NETs for which molecular targeted therapy or chemotherapy have failed (SCALET): TCOG T2221 study. ([`pubmed-observation-pmid-42976416-2026-11-13-3af6ea5f41c6`](#source-pubmed-observation-pmid-42976416-2026-11-13-3af6ea5f41c6))

#### Summary

PubMed lists PMID 42976416 in ESMO open as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42976416-2026-11-13-3af6ea5f41c6`](#source-pubmed-observation-pmid-42976416-2026-11-13-3af6ea5f41c6))

#### Paragraph 1

PubMed lists PMID 42976416 in ESMO open as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42976416-2026-11-13-3af6ea5f41c6`](#source-pubmed-observation-pmid-42976416-2026-11-13-3af6ea5f41c6))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42976416-2026-11-13-3af6ea5f41c6`](#source-pubmed-observation-pmid-42976416-2026-11-13-3af6ea5f41c6))

### Sources

<a id="source-pubmed-observation-pmid-42976416-2026-11-13-3af6ea5f41c6"></a>
- **A phase I/II study using cabozantinib and lanreotide as treatments for advanced GEP-NETs for which molecular targeted therapy or chemotherapy have failed (SCALET): TCOG T2221 study. · retained source version 1:2026-11-13:current:3af6ea5f41c67c1e8d84ce6ffc9fd67581d1248af12a09609544317f300deb90** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42976416/) (`pubmed-observation-pmid-42976416-2026-11-13-3af6ea5f41c6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A phase I/II study using cabozantinib and lanreotide as treatments for advanced GEP-NETs for which molecular targeted therapy or chemotherapy have failed (SCALET): TCOG T2221 study." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-42976416-lanreotide-v1 SHA-256: 709560d6d4c211f14a192764612212d368a46a188729e2c0f5f4cd0ce4d14d9e.

---

<a id="pubmed-pmid-7540120-lanreotide-v1"></a>

## PubMed record PMID 7540120

> PeptideScanner retained PubMed bibliographic metadata for PMID 7540120 at 2026-07-30T21:35:51.187Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1995-01-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-7540120-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-7540120-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-7540120-lanreotide-v1
- Content SHA-256: `9ad9d9b67f4a955f799f77104fbbaefa9814bcc13a93d01f8c04cb241dcded5d`

### Claims and source pins

#### Headline

PubMed record PMID 7540120 ([`pubmed-observation-pmid-7540120-2016-11-23-33b5ce2cd1ac`](#source-pubmed-observation-pmid-7540120-2016-11-23-33b5ce2cd1ac))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 7540120 at 2026-07-30T21:35:51.187Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1995-01-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-7540120-2016-11-23-33b5ce2cd1ac`](#source-pubmed-observation-pmid-7540120-2016-11-23-33b5ce2cd1ac))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 7540120 at 2026-07-30T21:35:51.187Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1995-01-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-7540120-2016-11-23-33b5ce2cd1ac`](#source-pubmed-observation-pmid-7540120-2016-11-23-33b5ce2cd1ac))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-7540120-2016-11-23-33b5ce2cd1ac`](#source-pubmed-observation-pmid-7540120-2016-11-23-33b5ce2cd1ac))

### Sources

<a id="source-pubmed-observation-pmid-7540120-2016-11-23-33b5ce2cd1ac"></a>
- **PubMed record PMID 7540120 · retained source version 1:2016-11-23:current:33b5ce2cd1ac45ab952e41b40eb8db052e6a80fc7c9a7a728878cf87d07fc288** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/7540120/) (`pubmed-observation-pmid-7540120-2016-11-23-33b5ce2cd1ac`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 7540120." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-7540120-lanreotide-v1 SHA-256: 9ad9d9b67f4a955f799f77104fbbaefa9814bcc13a93d01f8c04cb241dcded5d.

---

<a id="pubmed-pmid-7864583-lanreotide-v1"></a>

## PubMed record PMID 7864583

> PeptideScanner retained PubMed bibliographic metadata for PMID 7864583 at 2026-07-30T21:35:51.193Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1994-01-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-7864583-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-7864583-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-7864583-lanreotide-v1
- Content SHA-256: `9460016831b599718b8ae817199e216a266db5f97118ef87c42ae69d4d8cc085`

### Claims and source pins

#### Headline

PubMed record PMID 7864583 ([`pubmed-observation-pmid-7864583-2016-11-23-59d379984a4a`](#source-pubmed-observation-pmid-7864583-2016-11-23-59d379984a4a))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 7864583 at 2026-07-30T21:35:51.193Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1994-01-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-7864583-2016-11-23-59d379984a4a`](#source-pubmed-observation-pmid-7864583-2016-11-23-59d379984a4a))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 7864583 at 2026-07-30T21:35:51.193Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1994-01-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-7864583-2016-11-23-59d379984a4a`](#source-pubmed-observation-pmid-7864583-2016-11-23-59d379984a4a))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-7864583-2016-11-23-59d379984a4a`](#source-pubmed-observation-pmid-7864583-2016-11-23-59d379984a4a))

### Sources

<a id="source-pubmed-observation-pmid-7864583-2016-11-23-59d379984a4a"></a>
- **PubMed record PMID 7864583 · retained source version 1:2016-11-23:current:59d379984a4a9169346a9b665c3bb0befba80e32ce8821c86f9706f093838be6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/7864583/) (`pubmed-observation-pmid-7864583-2016-11-23-59d379984a4a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 7864583." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-7864583-lanreotide-v1 SHA-256: 9460016831b599718b8ae817199e216a266db5f97118ef87c42ae69d4d8cc085.

---

<a id="pubmed-pmid-8099735-lanreotide-v1"></a>

## \[Treatment of acromegaly with sustained-release lanreotide. A new somatostatin analog\].

> PubMed lists PMID 8099735 in Presse medicale (Paris, France : 1983) as Journal Article, with publication-date metadata of 1993-03-27 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-8099735-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-12-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8099735-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-8099735-lanreotide-v1
- Content SHA-256: `db9f5d01a6cd8bfb18bc65325163fff07bc7261087abe8f47cfee7474d91f217`

### Claims and source pins

#### Headline

\[Treatment of acromegaly with sustained-release lanreotide. A new somatostatin analog\]. ([`pubmed-observation-pmid-8099735-2016-12-09-c79dc4a68c38`](#source-pubmed-observation-pmid-8099735-2016-12-09-c79dc4a68c38))

#### Summary

PubMed lists PMID 8099735 in Presse medicale (Paris, France : 1983) as Journal Article, with publication-date metadata of 1993-03-27 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8099735-2016-12-09-c79dc4a68c38`](#source-pubmed-observation-pmid-8099735-2016-12-09-c79dc4a68c38))

#### Paragraph 1

PubMed lists PMID 8099735 in Presse medicale (Paris, France : 1983) as Journal Article, with publication-date metadata of 1993-03-27 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8099735-2016-12-09-c79dc4a68c38`](#source-pubmed-observation-pmid-8099735-2016-12-09-c79dc4a68c38))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8099735-2016-12-09-c79dc4a68c38`](#source-pubmed-observation-pmid-8099735-2016-12-09-c79dc4a68c38))

### Sources

<a id="source-pubmed-observation-pmid-8099735-2016-12-09-c79dc4a68c38"></a>
- **\[Treatment of acromegaly with sustained-release lanreotide. A new somatostatin analog\]. · retained source version 1:2016-12-09:current:c79dc4a68c382253ef4da8fcee618d6ad13bb2dabb894870643120d36a3f21e6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8099735/) (`pubmed-observation-pmid-8099735-2016-12-09-c79dc4a68c38`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Treatment of acromegaly with sustained-release lanreotide. A new somatostatin analog\]." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-8099735-lanreotide-v1 SHA-256: db9f5d01a6cd8bfb18bc65325163fff07bc7261087abe8f47cfee7474d91f217.

---

<a id="pubmed-pmid-8646723-lanreotide-v1"></a>

## PubMed record PMID 8646723

> PeptideScanner retained PubMed bibliographic metadata for PMID 8646723 at 2026-07-30T21:35:51.201Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1996-07-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-8646723-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8646723-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-8646723-lanreotide-v1
- Content SHA-256: `63e1aad831bbec3d2ac149d39a78d9f13961d2a626a1ce5cc5ccf647cd9c6553`

### Claims and source pins

#### Headline

PubMed record PMID 8646723 ([`pubmed-observation-pmid-8646723-2016-11-23-d37fa2753d58`](#source-pubmed-observation-pmid-8646723-2016-11-23-d37fa2753d58))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 8646723 at 2026-07-30T21:35:51.201Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1996-07-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-8646723-2016-11-23-d37fa2753d58`](#source-pubmed-observation-pmid-8646723-2016-11-23-d37fa2753d58))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 8646723 at 2026-07-30T21:35:51.201Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1996-07-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-8646723-2016-11-23-d37fa2753d58`](#source-pubmed-observation-pmid-8646723-2016-11-23-d37fa2753d58))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8646723-2016-11-23-d37fa2753d58`](#source-pubmed-observation-pmid-8646723-2016-11-23-d37fa2753d58))

### Sources

<a id="source-pubmed-observation-pmid-8646723-2016-11-23-d37fa2753d58"></a>
- **PubMed record PMID 8646723 · retained source version 1:2016-11-23:current:d37fa2753d58439ce4776bb9b1276b9c3f90900f1587cb130fa2885721aba88c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8646723/) (`pubmed-observation-pmid-8646723-2016-11-23-d37fa2753d58`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 8646723." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-8646723-lanreotide-v1 SHA-256: 63e1aad831bbec3d2ac149d39a78d9f13961d2a626a1ce5cc5ccf647cd9c6553.

---

<a id="pubmed-pmid-8786564-lanreotide-v1"></a>

## PubMed record PMID 8786564

> PeptideScanner retained PubMed bibliographic metadata for PMID 8786564 at 2026-07-30T21:35:51.203Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1996-03-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-8786564-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8786564-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-8786564-lanreotide-v1
- Content SHA-256: `3ee1a5b1070a343847c4da93fbb3272cf9a4fc5fb42e0a65152f1985088a401c`

### Claims and source pins

#### Headline

PubMed record PMID 8786564 ([`pubmed-observation-pmid-8786564-2016-11-23-6ce4b4c72697`](#source-pubmed-observation-pmid-8786564-2016-11-23-6ce4b4c72697))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 8786564 at 2026-07-30T21:35:51.203Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1996-03-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-8786564-2016-11-23-6ce4b4c72697`](#source-pubmed-observation-pmid-8786564-2016-11-23-6ce4b4c72697))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 8786564 at 2026-07-30T21:35:51.203Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1996-03-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-8786564-2016-11-23-6ce4b4c72697`](#source-pubmed-observation-pmid-8786564-2016-11-23-6ce4b4c72697))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8786564-2016-11-23-6ce4b4c72697`](#source-pubmed-observation-pmid-8786564-2016-11-23-6ce4b4c72697))

### Sources

<a id="source-pubmed-observation-pmid-8786564-2016-11-23-6ce4b4c72697"></a>
- **PubMed record PMID 8786564 · retained source version 1:2016-11-23:current:6ce4b4c726972468e9b6d739917cbbc3352f1bea0ddcf89788e67ebb39ee9a75** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8786564/) (`pubmed-observation-pmid-8786564-2016-11-23-6ce4b4c72697`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 8786564." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-8786564-lanreotide-v1 SHA-256: 3ee1a5b1070a343847c4da93fbb3272cf9a4fc5fb42e0a65152f1985088a401c.

---

<a id="pubmed-pmid-8813476-lanreotide-v1"></a>

## The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours.

> PubMed lists PMID 8813476 in Digestion as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 1996 (year precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-8813476-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-02-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8813476-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-8813476-lanreotide-v1
- Content SHA-256: `ff1712b48b6e7fd12aac559dd9f987d4a2cf324b904518f836be58c04adc6877`

### Claims and source pins

#### Headline

The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours. ([`pubmed-observation-pmid-8813476-2018-02-16-d4200e746a01`](#source-pubmed-observation-pmid-8813476-2018-02-16-d4200e746a01))

#### Summary

PubMed lists PMID 8813476 in Digestion as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 1996 (year precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8813476-2018-02-16-d4200e746a01`](#source-pubmed-observation-pmid-8813476-2018-02-16-d4200e746a01))

#### Paragraph 1

PubMed lists PMID 8813476 in Digestion as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 1996 (year precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8813476-2018-02-16-d4200e746a01`](#source-pubmed-observation-pmid-8813476-2018-02-16-d4200e746a01))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8813476-2018-02-16-d4200e746a01`](#source-pubmed-observation-pmid-8813476-2018-02-16-d4200e746a01))

### Sources

<a id="source-pubmed-observation-pmid-8813476-2018-02-16-d4200e746a01"></a>
- **The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours. · retained source version 1:2018-02-16:current:d4200e746a01c9a70fd14d7e9637543607bf5159be679c4e6c89ac3de5cc165a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8813476/) (`pubmed-observation-pmid-8813476-2018-02-16-d4200e746a01`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-8813476-lanreotide-v1 SHA-256: ff1712b48b6e7fd12aac559dd9f987d4a2cf324b904518f836be58c04adc6877.

---

<a id="pubmed-pmid-8931985-lanreotide-v1"></a>

## PubMed record PMID 8931985

> PeptideScanner retained PubMed bibliographic metadata for PMID 8931985 at 2026-07-30T21:35:51.205Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1996-09-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-8931985-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8931985-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-8931985-lanreotide-v1
- Content SHA-256: `e24d0b97b638cf03e056acd65919a0490267a3f579a5813b2edc97bb917dce1a`

### Claims and source pins

#### Headline

PubMed record PMID 8931985 ([`pubmed-observation-pmid-8931985-2016-11-23-cb461cfd4edb`](#source-pubmed-observation-pmid-8931985-2016-11-23-cb461cfd4edb))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 8931985 at 2026-07-30T21:35:51.205Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1996-09-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-8931985-2016-11-23-cb461cfd4edb`](#source-pubmed-observation-pmid-8931985-2016-11-23-cb461cfd4edb))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 8931985 at 2026-07-30T21:35:51.205Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1996-09-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-8931985-2016-11-23-cb461cfd4edb`](#source-pubmed-observation-pmid-8931985-2016-11-23-cb461cfd4edb))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8931985-2016-11-23-cb461cfd4edb`](#source-pubmed-observation-pmid-8931985-2016-11-23-cb461cfd4edb))

### Sources

<a id="source-pubmed-observation-pmid-8931985-2016-11-23-cb461cfd4edb"></a>
- **PubMed record PMID 8931985 · retained source version 1:2016-11-23:current:cb461cfd4edbf5165b18a8d89db3f21424c750b0573db1061963da630966596d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8931985/) (`pubmed-observation-pmid-8931985-2016-11-23-cb461cfd4edb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 8931985." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-8931985-lanreotide-v1 SHA-256: e24d0b97b638cf03e056acd65919a0490267a3f579a5813b2edc97bb917dce1a.

---

<a id="pubmed-pmid-8954072-lanreotide-v1"></a>

## PubMed record PMID 8954072

> PeptideScanner retained PubMed bibliographic metadata for PMID 8954072 at 2026-07-30T21:35:51.206Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1996-12-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-8954072-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8954072-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-8954072-lanreotide-v1
- Content SHA-256: `5fe36c59a6c39d0d64e8142e232cd48c3bbff2efeace467b01425a42ebde70c1`

### Claims and source pins

#### Headline

PubMed record PMID 8954072 ([`pubmed-observation-pmid-8954072-2016-11-24-66379f26b2de`](#source-pubmed-observation-pmid-8954072-2016-11-24-66379f26b2de))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 8954072 at 2026-07-30T21:35:51.206Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1996-12-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-8954072-2016-11-24-66379f26b2de`](#source-pubmed-observation-pmid-8954072-2016-11-24-66379f26b2de))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 8954072 at 2026-07-30T21:35:51.206Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1996-12-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-8954072-2016-11-24-66379f26b2de`](#source-pubmed-observation-pmid-8954072-2016-11-24-66379f26b2de))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8954072-2016-11-24-66379f26b2de`](#source-pubmed-observation-pmid-8954072-2016-11-24-66379f26b2de))

### Sources

<a id="source-pubmed-observation-pmid-8954072-2016-11-24-66379f26b2de"></a>
- **PubMed record PMID 8954072 · retained source version 1:2016-11-24:current:66379f26b2de6b313d85496538a6e6cc72d9005b3d83f23ff0bc286aae3097ab** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8954072/) (`pubmed-observation-pmid-8954072-2016-11-24-66379f26b2de`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 8954072." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-8954072-lanreotide-v1 SHA-256: 5fe36c59a6c39d0d64e8142e232cd48c3bbff2efeace467b01425a42ebde70c1.

---

<a id="pubmed-pmid-8975096-lanreotide-v1"></a>

## PubMed record PMID 8975096

> PeptideScanner retained PubMed bibliographic metadata for PMID 8975096 at 2026-07-30T21:35:51.206Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1996-09-07. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-8975096-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8975096-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-8975096-lanreotide-v1
- Content SHA-256: `491ebf672cabaf1eb5d63389bbf9d257b1576b48f20029e7d543526428e62f64`

### Claims and source pins

#### Headline

PubMed record PMID 8975096 ([`pubmed-observation-pmid-8975096-2016-11-23-a413a953942b`](#source-pubmed-observation-pmid-8975096-2016-11-23-a413a953942b))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 8975096 at 2026-07-30T21:35:51.206Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1996-09-07. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-8975096-2016-11-23-a413a953942b`](#source-pubmed-observation-pmid-8975096-2016-11-23-a413a953942b))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 8975096 at 2026-07-30T21:35:51.206Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1996-09-07. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-8975096-2016-11-23-a413a953942b`](#source-pubmed-observation-pmid-8975096-2016-11-23-a413a953942b))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8975096-2016-11-23-a413a953942b`](#source-pubmed-observation-pmid-8975096-2016-11-23-a413a953942b))

### Sources

<a id="source-pubmed-observation-pmid-8975096-2016-11-23-a413a953942b"></a>
- **PubMed record PMID 8975096 · retained source version 1:2016-11-23:current:a413a953942b1bf55943dbd43cbc090d7acea438f3916ffc0c97c182e3bd22ae** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8975096/) (`pubmed-observation-pmid-8975096-2016-11-23-a413a953942b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 8975096." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-8975096-lanreotide-v1 SHA-256: 491ebf672cabaf1eb5d63389bbf9d257b1576b48f20029e7d543526428e62f64.

---

<a id="pubmed-pmid-9119171-lanreotide-v1"></a>

## PubMed record PMID 9119171

> PeptideScanner retained PubMed bibliographic metadata for PMID 9119171 at 2026-07-30T21:35:52.319Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1996-01-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-9119171-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9119171-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-9119171-lanreotide-v1
- Content SHA-256: `2fac83fb23a3d9de4fa3d9ca5aa875bbd10ae81fce8f511673187c468993a03f`

### Claims and source pins

#### Headline

PubMed record PMID 9119171 ([`pubmed-observation-pmid-9119171-2016-11-24-9568ef762c12`](#source-pubmed-observation-pmid-9119171-2016-11-24-9568ef762c12))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 9119171 at 2026-07-30T21:35:52.319Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1996-01-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-9119171-2016-11-24-9568ef762c12`](#source-pubmed-observation-pmid-9119171-2016-11-24-9568ef762c12))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 9119171 at 2026-07-30T21:35:52.319Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1996-01-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-9119171-2016-11-24-9568ef762c12`](#source-pubmed-observation-pmid-9119171-2016-11-24-9568ef762c12))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9119171-2016-11-24-9568ef762c12`](#source-pubmed-observation-pmid-9119171-2016-11-24-9568ef762c12))

### Sources

<a id="source-pubmed-observation-pmid-9119171-2016-11-24-9568ef762c12"></a>
- **PubMed record PMID 9119171 · retained source version 1:2016-11-24:current:9568ef762c121f4150cf6b754c5bd6d327c06183f326b9420f01e0731ad224c6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9119171/) (`pubmed-observation-pmid-9119171-2016-11-24-9568ef762c12`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 9119171." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-9119171-lanreotide-v1 SHA-256: 2fac83fb23a3d9de4fa3d9ca5aa875bbd10ae81fce8f511673187c468993a03f.

---

<a id="pubmed-pmid-9537429-lanreotide-v1"></a>

## PubMed record PMID 9537429

> PeptideScanner retained PubMed bibliographic metadata for PMID 9537429 at 2026-07-30T21:35:52.324Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1998-04-16. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-9537429-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9537429-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-9537429-lanreotide-v1
- Content SHA-256: `00c588f521705c1c62d677da17057b658409a0d1057c7107e1f360c2369bfc73`

### Claims and source pins

#### Headline

PubMed record PMID 9537429 ([`pubmed-observation-pmid-9537429-2016-11-24-dd929599971d`](#source-pubmed-observation-pmid-9537429-2016-11-24-dd929599971d))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 9537429 at 2026-07-30T21:35:52.324Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1998-04-16. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-9537429-2016-11-24-dd929599971d`](#source-pubmed-observation-pmid-9537429-2016-11-24-dd929599971d))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 9537429 at 2026-07-30T21:35:52.324Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1998-04-16. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-9537429-2016-11-24-dd929599971d`](#source-pubmed-observation-pmid-9537429-2016-11-24-dd929599971d))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9537429-2016-11-24-dd929599971d`](#source-pubmed-observation-pmid-9537429-2016-11-24-dd929599971d))

### Sources

<a id="source-pubmed-observation-pmid-9537429-2016-11-24-dd929599971d"></a>
- **PubMed record PMID 9537429 · retained source version 1:2016-11-24:current:dd929599971d3a5a6dd159e2103f7f2c49a7e73cab44ffec4b6589c56f025f20** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9537429/) (`pubmed-observation-pmid-9537429-2016-11-24-dd929599971d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 9537429." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-9537429-lanreotide-v1 SHA-256: 00c588f521705c1c62d677da17057b658409a0d1057c7107e1f360c2369bfc73.

---

<a id="pubmed-pmid-9867148-lanreotide-v1"></a>

## PubMed record PMID 9867148

> PeptideScanner retained PubMed bibliographic metadata for PMID 9867148 at 2026-07-30T21:35:52.335Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1998-12-29. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-9867148-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9867148-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-9867148-lanreotide-v1
- Content SHA-256: `151d53c713d36060956b33ee55472b23fff65364625d3224e7ad3198ce8017c3`

### Claims and source pins

#### Headline

PubMed record PMID 9867148 ([`pubmed-observation-pmid-9867148-2016-11-24-db844deeb322`](#source-pubmed-observation-pmid-9867148-2016-11-24-db844deeb322))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 9867148 at 2026-07-30T21:35:52.335Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1998-12-29. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-9867148-2016-11-24-db844deeb322`](#source-pubmed-observation-pmid-9867148-2016-11-24-db844deeb322))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 9867148 at 2026-07-30T21:35:52.335Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1998-12-29. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-9867148-2016-11-24-db844deeb322`](#source-pubmed-observation-pmid-9867148-2016-11-24-db844deeb322))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9867148-2016-11-24-db844deeb322`](#source-pubmed-observation-pmid-9867148-2016-11-24-db844deeb322))

### Sources

<a id="source-pubmed-observation-pmid-9867148-2016-11-24-db844deeb322"></a>
- **PubMed record PMID 9867148 · retained source version 1:2016-11-24:current:db844deeb322b4ed3bb246ffb594148350bb1faedfc314af11e640b8d3bf7977** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9867148/) (`pubmed-observation-pmid-9867148-2016-11-24-db844deeb322`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 9867148." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-9867148-lanreotide-v1 SHA-256: 151d53c713d36060956b33ee55472b23fff65364625d3224e7ad3198ce8017c3.

---

<a id="pubmed-pmid-9934776-lanreotide-v1"></a>

## PubMed record PMID 9934776

> PeptideScanner retained PubMed bibliographic metadata for PMID 9934776 at 2026-07-30T21:35:52.335Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1999-02-06. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-9934776-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9934776-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-9934776-lanreotide-v1
- Content SHA-256: `60995943a2e88f805790f3cde2b8a37238be03f7fdb5a78dc0e2b294e83284d6`

### Claims and source pins

#### Headline

PubMed record PMID 9934776 ([`pubmed-observation-pmid-9934776-2016-11-24-70f7210198b9`](#source-pubmed-observation-pmid-9934776-2016-11-24-70f7210198b9))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 9934776 at 2026-07-30T21:35:52.335Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1999-02-06. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-9934776-2016-11-24-70f7210198b9`](#source-pubmed-observation-pmid-9934776-2016-11-24-70f7210198b9))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 9934776 at 2026-07-30T21:35:52.335Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1999-02-06. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-9934776-2016-11-24-70f7210198b9`](#source-pubmed-observation-pmid-9934776-2016-11-24-70f7210198b9))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9934776-2016-11-24-70f7210198b9`](#source-pubmed-observation-pmid-9934776-2016-11-24-70f7210198b9))

### Sources

<a id="source-pubmed-observation-pmid-9934776-2016-11-24-70f7210198b9"></a>
- **PubMed record PMID 9934776 · retained source version 1:2016-11-24:current:70f7210198b9239c9571f33500eeb8979cfc96b1b06d62bbaac6ad00aebcdf08** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9934776/) (`pubmed-observation-pmid-9934776-2016-11-24-70f7210198b9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 9934776." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/lanreotide.json#pubmed-pmid-9934776-lanreotide-v1 SHA-256: 60995943a2e88f805790f3cde2b8a37238be03f7fdb5a78dc0e2b294e83284d6.

